[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 172
1. Butnor KJ: My approach to the diagnosis of mesothelial lesions. J Clin Pathol; 2006 Jun;59(6):564-74
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] My approach to the diagnosis of mesothelial lesions.
  • Mesothelial lesions pose considerable diagnostic challenges not only because benign tumours, reactive proliferations and malignant mesothelioma can mimic one another, but also because the morphological patterns displayed by malignant mesothelioma can simulate a variety of epithelial and non-epithelial malignancies.
  • Immunohistochemical markers can aid in distinguishing epithelioid malignant mesothelioma from metastatic adenocarcinoma, but because no single marker reliably separates all cases, a panel of stains is recommended.
  • Immunohistochemical studies are of more limited value in sarcomatoid malignant mesothelioma, and other features often play an essential role.
  • The separation of reactive mesothelial proliferations from malignant mesothelioma on small biopsy can be quite difficult, as distinguishing features, such as stromal invasion, often cannot be adequately assessed.
  • In adequately sampled lesions, however, the distinction between malignant mesothelioma, benign mesothelial proliferations and other tumours can be achieved in most cases by using a carefully integrated approach that incorporates clinical and radiographic data, immunohistochemical studies and, in selected cases, histochemical and ultrastructural techniques.
  • [MeSH-major] Mesothelioma / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / secondary. Biomarkers, Tumor / metabolism. Cell Proliferation. Diagnosis, Differential. Epithelium / pathology. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1997 Jul;31(1):25-30 [9253621.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1399-408 [9414183.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1409-19 [9414184.001]
  • [Cites] Am J Clin Pathol. 1998 Jan;109(1):85-9 [9426522.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):583-90 [9452278.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):166-9 [9490276.001]
  • [Cites] Cancer Lett. 1998 Feb 13;124(1):73-8 [9500194.001]
  • [Cites] Am J Surg Pathol. 1998 Mar;22(3):285-92 [9580050.001]
  • [Cites] Histopathology. 1998 Mar;32(3):209-16 [9568505.001]
  • [Cites] Histopathology. 1998 May;32(5):462-72 [9639123.001]
  • [Cites] Histopathology. 2000 Sep;37(3):224-31 [10971698.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1183-200 [10976692.001]
  • [Cites] AJR Am J Roentgenol. 2000 Dec;175(6):1545-9 [11090371.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):610-7 [11342772.001]
  • [Cites] Am J Clin Pathol. 2001 Aug;116(2):246-52 [11488072.001]
  • [Cites] Am J Clin Pathol. 2001 Aug;116(2):253-62 [11488073.001]
  • [Cites] Arch Pathol Lab Med. 2001 Oct;125(10):1316-20 [11570906.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1304-9 [11688466.001]
  • [Cites] Arch Pathol Lab Med. 2001 Dec;125(12):1588-90 [11735696.001]
  • [Cites] Mod Pathol. 2002 Jan;15(1):6-10 [11796835.001]
  • [Cites] Am J Clin Pathol. 1998 Aug;110(2):191-9 [9704618.001]
  • [Cites] Int J Cancer. 1998 Oct 5;78(2):182-8 [9754650.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1215-21 [9777983.001]
  • [Cites] Mod Pathol. 1998 Oct;11(10):929-33 [9796717.001]
  • [Cites] Hum Pathol. 1999 Mar;30(3):313-23 [10088551.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):105-10 [15389250.001]
  • [Cites] Mod Pathol. 2003 Feb;16(2):137-44 [12591966.001]
  • [Cites] Histopathology. 2003 Mar;42(3):270-9 [12605647.001]
  • [Cites] J Pathol. 2003 Apr;199(4):479-87 [12635139.001]
  • [Cites] Mod Pathol. 2003 Mar;16(3):192-7 [12640097.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):605-9 [12827615.001]
  • [Cites] J Thorac Imaging. 2003 Jul;18(3):200-3 [12867819.001]
  • [Cites] Histopathology. 2003 Sep;43(3):231-8 [12940775.001]
  • [Cites] Histopathology. 2003 Nov;43(5):444-52 [14636270.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):534-40 [15087673.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):697-710 [15188136.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):449-55 [15297187.001]
  • [Cites] Ann Thorac Surg. 2004 Nov;78(5):1774-6 [15511473.001]
  • [Cites] Am J Clin Pathol. 1976 Feb;65(2):159-67 [175652.001]
  • [Cites] Am J Pathol. 1982 Jul;108(1):80-8 [6178295.001]
  • [Cites] Am J Surg Pathol. 1982 Apr;6(3):215-22 [7102900.001]
  • [Cites] Arch Pathol Lab Med. 1987 Jan;111(1):62-6 [3099726.001]
  • [Cites] Pathol Annu. 1987;22 Pt 2:91-131 [2825103.001]
  • [Cites] Ultrastruct Pathol. 1987;11(5-6):503-33 [3318058.001]
  • [Cites] Ultrastruct Pathol. 1988;12(4):367-84 [2458647.001]
  • [Cites] Pathol Annu. 1989;24 Pt 1:303-53 [2654842.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1336-46 [2766227.001]
  • [Cites] Histopathology. 2000 Apr;36(4):341-7 [10759948.001]
  • [Cites] Cancer. 1990 Jan 15;65(2):292-6 [2295052.001]
  • [Cites] Hum Pathol. 1990 Jul;21(7):759-66 [2193875.001]
  • [Cites] Histopathology. 1992 Jan;20(1):47-51 [1310669.001]
  • [Cites] J Clin Pathol. 1992 Apr;45(4):295-8 [1577967.001]
  • [Cites] Histopathology. 1992 Nov;21(5):453-7 [1280615.001]
  • [Cites] Histopathology. 1993 Jun;22(6):601-2 [8354495.001]
  • [Cites] Am J Surg Pathol. 1994 Apr;18(4):357-63 [7511353.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):439-45 [7513500.001]
  • [Cites] Hum Pathol. 1994 Aug;25(8):753-7 [7520015.001]
  • [Cites] Hum Pathol. 1995 Apr;26(4):428-31 [7535740.001]
  • [Cites] Semin Diagn Pathol. 1995 Feb;12(1):30-44 [7770673.001]
  • [Cites] Am J Surg Pathol. 1995 Oct;19(10):1124-37 [7573671.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):189-94 [8607443.001]
  • [Cites] Am J Surg Pathol. 1996 Sep;20(9):1037-46 [8764740.001]
  • [Cites] Pathol Res Pract. 1995 Nov;191(11):1147-52 [8822117.001]
  • [Cites] Ultrastruct Pathol. 2004 Jul-Aug;28(4):213-28 [15693633.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Mar;13(1):75-9 [15722797.001]
  • [Cites] Am J Pathol. 2005 Mar;166(3):913-21 [15743802.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):372-80 [15891998.001]
  • [Cites] Hum Pathol. 2005 May;36(5):465-73 [15948112.001]
  • [Cites] Am J Surg Pathol. 2005 Jul;29(7):866-73 [15958850.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):724-37 [15981812.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):34-48 [16056246.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1203-14 [9777982.001]
  • [Cites] Am J Clin Pathol. 2000 May;113(5):649-54 [10800396.001]
  • [Cites] Semin Diagn Pathol. 2000 Aug;17(3):184-93 [10968704.001]
  • [Cites] J Postgrad Med. 2002 Jan-Mar;48(1):29-31 [12082324.001]
  • [Cites] Histopathology. 2002 Jul;41(1):42-9 [12121236.001]
  • [Cites] Histopathology. 2002 Oct;41(4):301-7 [12383211.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):150-8 [12548160.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3443-8 [12552937.001]
  • [Cites] Arch Pathol Lab Med. 2003 Feb;127(2):193-5 [12562233.001]
  • [Cites] Chest. 1997 Jan;111(1):106-9 [8996002.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):29-34 [10665909.001]
  • [Cites] Mod Pathol. 2000 Feb;13(2):107-12 [10697265.001]
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):598-606 [10757409.001]
  • (PMID = 16731600.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC1860395
  •  go-up   go-down


2. Barry P, Chan KG, Hsu J, Quek ML: Adenomatoid tumor of the tunica albuginea. Int J Urol; 2005 May;12(5):516-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatoid tumor of the tunica albuginea.
  • Adenomatoid tumors are benign mesothelial tumors most commonly found in the paratesticular structures, especially the epididymis.
  • Herein, we report a case of adenomatoid tumor originating in the tunica albuginea and mimicking an intratesticular neoplasm.
  • We review the ultrasonographic presentation and literature regarding adenomatoid tumors originating in the tunica albuginea and testicular parenchyma.
  • [MeSH-major] Adenomatoid Tumor / pathology. Testicular Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948758.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


3. Davidson B, Skrede M, Silins I, Shih IeM, Trope CG, Flørenes VA: Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. Cancer; 2007 Sep 15;110(6):1264-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma.
  • BACKGROUND: The authors recently reported on the role of cyclin E in differentiating ovarian/primary peritoneal carcinoma from malignant peritoneal mesothelioma using gene expression arrays.
  • In the current study, they analyzed the expression of low-molecular weight (LMW) forms of cyclin E in ovarian carcinoma, malignant mesothelioma, and benign reactive effusions.
  • METHODS: Cyclin E protein expression was analyzed in 98 effusions (72 ovarian carcinomas, 14 malignant mesotheliomas, and 12 reactive specimens) using immunoblotting.
  • RESULTS: LMW forms of cyclin E were identified in 54 of 72 ovarian carcinoma effusions (75%) compared with 1 of 14 malignant mesothelioma effusions (7%) and 1 of 12 reactive effusions (8%) (P < .001).
  • The presence of a higher percentage of cyclin E-positive cells using immunohistochemistry was correlated with shorter progression-free survival (P = .026).
  • CONCLUSIONS: LMW forms of cyclin E differentiated ovarian carcinoma from benign and malignant mesothelial cells and were associated with increased protein expression using immunohistochemistry.
  • The expression of LMW cyclin E forms was not associated with chemotherapy response, although it may be a marker of aggressive disease in patients with metastatic ovarian carcinoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / chemistry. Carcinoma / mortality. Cyclin E / analysis. Mesothelioma / chemistry. Mesothelioma / mortality. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Immunoblotting. Immunohistochemistry. Middle Aged. Molecular Weight. Survival Analysis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17647260.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin E
  •  go-up   go-down


Advertisement
4. Białas M, Szczepański W, Szpor J, Okoń K, Kostecka-Matyja M, Hubalewska-Dydejczyk A, Tomaszewska R: Adenomatoid tumour of the adrenal gland: a case report and literature review. Pol J Pathol; 2010;61(2):97-102
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatoid tumour of the adrenal gland: a case report and literature review.
  • Adenomatoid tumour (AT) is a rare, benign neoplasm of mesothelial origin, which usually occurs in the genital tract of both sexes.
  • Occasionally these tumours are found in extra genital locations such as heart, pancreas, skin, pleura, omentum, lymph nodes, retroperitoneum, intestinal mesentery and adrenal gland.
  • The most important thing about these tumours is not to mis-diagnose them as primary malignant or metastatic neoplasms.
  • The tumour was an incidental finding during abdominal CT-scan for an unrelated condition.
  • [MeSH-major] Adenomatoid Tumor / pathology. Adrenal Gland Neoplasms / pathology
  • [MeSH-minor] Adult. Asymptomatic Diseases. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Incidental Findings. Male. Radiography, Abdominal. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20924994.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


5. Pila Pérez R, Rosales Torres P, Pila Peláez R, Holguín Prieto V, Torres Vargas E: [Adenomatoid tumor of the epididymis: an infrequent case]. Arch Esp Urol; 2009 Oct;62(8):656-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumor of the epididymis: an infrequent case].
  • [Transliterated title] Tumor adenomatoide del epidídimo: una infrecuente observación.
  • OBJECTIVES: To present a new case of adenomatoid tumor of the epididymis, the first report in our hospital since 1962.
  • METHODS: We report a clinical case with a brief bibliographic review about adenomatoid tumor of the epididymis.
  • Physical examination and ultrasound study demonstrated a tumor of 5x5x2 cm.
  • It was removed and the histopathological study was compatible with adenomatoid tumor of the epididymis.
  • CONCLUSION: The adenomatoid tumor of the epididymis is a neoplasm located in the paratesticular region, however it can be found infrequently in other sites.
  • Mesothelial origin has been mentioned and inflammation has played some role in the development of these tumors.
  • It can minimally invade adjacent structures, though it is benign without metastatic potential.
  • [MeSH-major] Adenomatoid Tumor. Epididymis. Genital Neoplasms, Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19893140.001).
  • [ISSN] 1576-8260
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


6. Bansal A, Zakhour HD: Benign mesothelioma of the appendix: an incidental finding in a case of sigmoid diverticular disease. J Clin Pathol; 2006 Jan;59(1):108-10
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign mesothelioma of the appendix: an incidental finding in a case of sigmoid diverticular disease.
  • Benign multicystic mesothelioma is a well recognised but rare entity.
  • The aim of this report is to describe a case of a small mesothelial proliferation of the peritoneum.
  • An operation was performed for symptomatic sigmoid diverticular disease.
  • Microscopy revealed a benign mesothelioma.
  • [MeSH-major] Appendiceal Neoplasms / diagnosis. Diverticulum / complications. Mesothelioma / diagnosis. Sigmoid Diseases / complications

  • Genetic Alliance. consumer health - Diverticular Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chir Ital. 2002 Jul-Aug;54(4):569-72 [12239771.001]
  • [Cites] Am J Surg Pathol. 1986 Dec;10(12):844-54 [3789251.001]
  • [Cites] Am J Surg Pathol. 1990 Apr;14(4):375-8 [2181883.001]
  • [Cites] J Korean Med Sci. 1989 Jun;4(2):111-5 [2597362.001]
  • [Cites] G Ital Oncol. 1989 Jan-Mar;9(1):39-42 [2707838.001]
  • (PMID = 16394291.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1860251
  •  go-up   go-down


7. Amin W, Parwani AV: Adenomatoid tumor of testis. Clin Med Pathol; 2009;2:17-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatoid tumor of testis.
  • Adenomatoid tumors are responsible for 30% of all paratesticular masses.
  • They are benign tumors comprising of cords and tubules of cuboidal to columnar cells with vacuolated cytoplasm and fibrous stroma.
  • They are considered to be of mesothelial origin supported by histochemical studies and genetic analysis of Wilms tumor 1 gene expression.
  • Diagnostic studies include serum tumor markers (negative alpha fetoprotein, beta HCG, LDH) ultrasonography (hypoechoic and homogenous appearance) and frozen section.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21151545.001).
  • [ISSN] 1178-1181
  • [Journal-full-title] Clinical medicine. Pathology
  • [ISO-abbreviation] Clin Med Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2990235
  • [Keywords] NOTNLM ; adenomatoid tumor / paratesticluar masses
  •  go-up   go-down


8. Mourali M, Kedous Z, El Fekih C, Ben Haj Hassine A, Ayadi A, Zineb NB: [Unexpected diagnosis of a cystic pelvic mass: benign mesothelioma of the uterus: case report]. Tunis Med; 2010 Aug;88(8):605-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unexpected diagnosis of a cystic pelvic mass: benign mesothelioma of the uterus: case report].
  • [Transliterated title] Diagnostic Inattendu devant une masse kystique pelvienne : mésotheliome bénin de l’utérus. A propos d’un cas.
  • BACKGROUND: Benign mesothelioma is a rare tumour mostly found in the genital tract.
  • Histologic exam and immnunochemistry concluded to a benign cystic mesothelioma.
  • CONCLUSION: The benign mesothelioma of the uterus is usually discovered in histology, differential diagnosis for solid forms can be made with leiomyoma or adenomyoma, whereas the cystic forms can be discussed essentially with the ovarian cysts.
  • The presence of mesothelial immunophenotype in immunochemistry improves diagnosis.
  • [MeSH-major] Mesothelioma, Cystic. Uterine Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20711970.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


9. Leaha C, Opris I, Macé P, Resch B, Sabourin JC: [Cystic adenomatoid tumor of the uterus]. Ann Pathol; 2009 Apr;29(2):134-7
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cystic adenomatoid tumor of the uterus].
  • [Transliterated title] Tumeur adénomatoïde kystique utérine.
  • Adenomatoid tumors are benign neoplasms of mesothelial origin, which involve the feminine and masculine genital tracts.
  • Our study presents an adenomatoid tumour, of cystic shape, which enables discussion of the histogenesis of this tumour and enlightenment of differential diagnoses which can at times result in an incorrect malignant diagnosis.
  • [MeSH-major] Adenomatoid Tumor / pathology. Uterine Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19364588.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G
  •  go-up   go-down


10. Tursi M, Martinetti M, Gili S, Muscio M, Gay L, Crudelini M, Cenacchi G, Pucci A: Myocardial adenomatoid tumor in eight cattle: evidence for mesothelial origin of bovine myocardial epithelial inclusions. Vet Pathol; 2009 Sep;46(5):897-903
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myocardial adenomatoid tumor in eight cattle: evidence for mesothelial origin of bovine myocardial epithelial inclusions.
  • The adenomatoid tumor is an uncommon benign lesion, thus far described only in humans.
  • Adenomatoid tumors typically arise in the genital tract, exceptionally in the heart, and usually represent an incidental finding.
  • Mesothelial origin of these lesions is suggested by their immunohistochemical characteristics.
  • In cattle, previously reported myocardial epithelial inclusions are morphologically similar in that the cells are immunoreactive for both cytokeratins and vimentin, and bear surface microvilli.
  • Myocardial lesions found incidentally at slaughter in 8 cattle histologically resembled the so-called bovine myocardial epithelial inclusions and had morphologic and immunohistochemical features consistent with human adenomatoid tumor.
  • All lesions were in the left ventricular myocardium, adjacent to the epicardium, and composed of epithelioid cells that formed cords and tubules, and were immunoreactive for pan-cytokeratins, cytokeratin 5/6, vimentin, calretinin, Wilms' tumor 1 suppressor gene, and CD30 antigen.
  • The immunohistochemical and ultrastructural features were considered consistent with mesothelial origin.
  • These lesions, corresponding to the previously described myocardial epithelial inclusions in cattle, might be considered embryologic rests and could represent the bovine counterpart of the human adenomatoid tumor.
  • [MeSH-major] Adenomatoid Tumor / veterinary. Cattle Diseases / pathology. Heart Neoplasms / veterinary. Neoplasms, Mesothelial / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19430001.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Alvarez Maestro M, Tur Gonzalez R, Alonso Dorrego JM, Jesus De la Peña Barthel J, Nistal Martin De Serrano M: [Adenomatoid tumors of the epididymis and testicle: report of 9 cases and bibliographic review]. Arch Esp Urol; 2009 Mar;62(2):137-41
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumors of the epididymis and testicle: report of 9 cases and bibliographic review].
  • [Transliterated title] Tumor adenomatoide de epidídimo intratesticular: A proposito de nueve casos y revisión de la literatura.
  • BACKGROUND: To report the cases of adenomatoid tumors seen at Hospital Universitario La Paz in the last 15 years.
  • METHODS: A clinical, pathological, and surgical study was conducted of males with testicular or paratesticular tumors with a histological report of adenomatoid tumor.
  • RESULTS: Among the nine cases studied, seven had paratesticular and two intratesticular adenomatoid tumors.
  • Treatment of choice was mass removal for epididymal tumors and orchidectomy for intratesticular tumors.
  • CONCLUSIONS: Adenomatoid tumors are uncommon benign neoplasms of a possible mesothelial origin.
  • Because of their benign nature, the treatment of choice is local excision (conservative surgery), but orchidectomy was performed in two cases due to tumor location.
  • [MeSH-major] Adenomatoid Tumor. Epididymis. Genital Neoplasms, Male. Testicular Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19448282.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 10
  •  go-up   go-down


12. Cakir C, Gulluoglu MG, Yilmazbayhan D: Cell proliferation rate and telomerase activity in the differential diagnosis between benign and malignant mesothelial proliferations. Pathology; 2006 Feb;38(1):10-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell proliferation rate and telomerase activity in the differential diagnosis between benign and malignant mesothelial proliferations.
  • AIMS: The differential diagnosis of malignant mesothelioma (MM) from benign mesothelial lesions (BML) based on histopathological criteria is sometimes not satisfying and causes diagnostic problems for histopathologists.
  • METHODS: Sixty-six cases of MM (33 epithelioid, 30 biphasic and 3 sarcomatoid) and 22 cases of BML (15 reactive mesothelial proliferations and 7 fibrous pleuritis/pericarditis) were included in this study.
  • CONCLUSION: As a result, being cheap and simple methods, Ki-67 and hTERT immunohistochemistries can be used in differentiating malignant and benign mesothelial lesions in routine formalin-fixed, paraffin-embedded material.
  • [MeSH-major] Cell Proliferation. Neoplasms, Mesothelial / metabolism. Neoplasms, Mesothelial / pathology. Telomerase / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. DNA-Binding Proteins / metabolism. Diagnosis, Differential. Female. Humans. Hyperplasia / pathology. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Pleurisy / diagnosis. Pleurisy / metabolism. Pleurisy / pathology. Predictive Value of Tests. Sensitivity and Specificity

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484001.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


13. Taheri ZM, Mehrafza M, Mohammadi F, Khoddami M, Bahadori M, Masjedi MR: The diagnostic value of Ki-67 and repp86 in distinguishing between benign and malignant mesothelial proliferations. Arch Pathol Lab Med; 2008 Apr;132(4):694-7
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic value of Ki-67 and repp86 in distinguishing between benign and malignant mesothelial proliferations.
  • CONTEXT: The differentiation of benign mesothelial proliferations from malignant mesotheliomas may be difficult, especially when evaluating small specimens from pleural biopsies.
  • OBJECTIVE: To explore the potential value of 2 proliferative cell markers, Ki-67 and restrictedly expressed proliferation-associated protein 86 kDa (repp86), in distinguishing between malignant mesothelioma (MM) and benign reactive mesothelial hyperplasia (MH).
  • DESIGN: Thirty-six cases of MM from 26 men and 10 women with a mean age of 62.9 years (range, 36-80 years) and 22 cases of benign reactive MH from 14 male and 8 female patients with a mean age of 51.5 years (range, 15- 88 years) were included in this study.
  • RESULTS: The mean labeling indexes for Ki-67 in MM and benign reactive MH were 24.6% (range, 1%-66%) and 6.23% (range, 0%-25%), respectively.
  • The mean labeling indexes for repp86 in MM and benign reactive MH were 26.3% (range, 0%-50%) and 3.26% (range, 0%- 21%), respectively.
  • The average proliferative cell count was significantly higher in MM compared with benign reactive MH (P < .001).
  • Furthermore, both markers showed a significant correlation in their expression in MM and benign reactive MH (r = 77.5, P < .001).
  • CONCLUSIONS: Used in combination, Ki-67 and repp86 appear to be useful markers in differentiating MM from benign reactive MH.
  • [MeSH-major] Epithelium / metabolism. Ki-67 Antigen / metabolism. Mesothelioma / diagnosis. Mesothelioma / metabolism. Neoplasms, Mesothelial / diagnosis. Neoplasms, Mesothelial / metabolism. Nuclear Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / immunology. Biomarkers / metabolism. Biomarkers, Tumor / metabolism. Cell Proliferation. Diagnosis, Differential. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / metabolism. Hyperplasia / pathology. Male. Middle Aged. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18384222.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; 0 / SND1 protein, human
  •  go-up   go-down


14. Bestard Vallejo JE, Tremps Velázquez E, Blázquez Mañá C, Celma Doménech A, de Torres Ramírez I, Morote Robles J: [Adenomatoid tumour of epididymis: the most common tumour of the paratesticular structures]. Actas Urol Esp; 2008 Jun;32(6):611-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumour of epididymis: the most common tumour of the paratesticular structures].
  • [Transliterated title] Tumor adenomatoide de epididimo: el tumor más frecuente de las estructuras paratesticulares.
  • INTRODUCTION: Paratesticular tumours are rare but generally benign neoplasms, usually treated by local excission.
  • Adenomatoid tumours of epididymis are the most common of these tumours.
  • OBJECTIVES: Analyze paratesticular tumours treated in our center and describe dyagnosis and treatment of adenomatoid tumours of epididymis.
  • MATERIAL AND METHODS: We retrospectively review 8 patients with paratesticular tumours treated from July 1997 to July 2007.
  • RESULTS: Patients median age was 44.1 years (22-69), presenting most of them subacute scrotal tumour with median size by ultrasound of 2.8 cm (1.5-7).
  • All of them were locally extirpated except one with suspicion of a malignant polyorchidism and another one with an apparently intratesticular lesion of great size.
  • Dyagnosis was in 4 cases adenomatoid tumour of epididymis, in two cases fibrous pseudotumour of epididymis, in one case leiomyoma of epididymis and in one case angiolipoma of spermatic cord.
  • Just in one case diagnosed of adenomatoid tumour of epididymis ultrasound confirmed solid tumour suggesting the final dyagnosis.
  • CONCLUSIONS: Adenomatoid tumors of epididymis are rare tumours which may present at any age.
  • Benignity of adenomatoid tumour of epididymis as well as most of the other paratesticular tumours should make local excission the treatment of choice and, when any doubt existed, peroperatory biopsy should be performed.
  • [MeSH-major] Adenomatoid Tumor. Epididymis. Genital Neoplasms, Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18655344.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 19
  •  go-up   go-down


15. Lehsnau M, Hecht L: [Adenomatoid tumor of the testes--a rare entity. Clinical, diagnostic and therapeutic aspects]. Urologe A; 2006 Nov;45(11):1431-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumor of the testes--a rare entity. Clinical, diagnostic and therapeutic aspects].
  • [Transliterated title] Adenomatoidtumor des Hodens--eine seltene Entität. Klinische, diagnostische und therapeutische Aspekte.
  • Adenomatoid tumor with intra-testicular localization is rare.
  • Adenomatoid tumors occur in both sexes and are also found in the uterus, ovary and fallopian tubes of the female genital tract.
  • Adenomatoid tumors are benign proliferations of mesothelial origin.
  • We report the case of a 50-year-old male with an adenomatoid tumor of the left testis.
  • [MeSH-major] Adenomatoid Tumor / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy. Calbindin 2. Diagnosis, Differential. Humans. Keratins / analysis. Male. Middle Aged. Orchiectomy. Prognosis. S100 Calcium Binding Protein G / analysis. Testis / pathology. Tomography, X-Ray Computed. Ultrasonography. Vimentin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Jan;28(1):77-83 [14707867.001]
  • [Cites] Eur Urol. 1996;30(1):127-8 [8854081.001]
  • [Cites] Urology. 2004 Sep;64(3):589 [15351601.001]
  • [Cites] Urology. 2004 Apr;63(4):779-81 [15072910.001]
  • [Cites] J Urol. 1991 Jul;146(1):61-5 [2056607.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2002 Jun;10(2):159-62 [12051635.001]
  • [Cites] J Urol. 2003 Nov;170(5):1783-6 [14532776.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):994-1000 [14608532.001]
  • [Cites] BJU Int. 2000 Feb;85(3):302-4 [10671886.001]
  • [Cites] Int J Gynecol Pathol. 2004 Apr;23(2):97-9 [15084836.001]
  • [Cites] J Pathol. 1986 Apr;148(4):327-35 [3517266.001]
  • [Cites] Am J Pathol. 1945 Jan;21(1):63-79 [19970804.001]
  • [Cites] J Urol. 1981 Nov;126(5):709 [6117663.001]
  • [Cites] J Urol. 2004 May;171(5):1765-72 [15076274.001]
  • [Cites] Histopathology. 2000 Feb;36(2):109-15 [10672054.001]
  • (PMID = 16933122.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


16. Rappa F, Ternullo MP: [Adenomatoid tumor]. Pathologica; 2006 Apr;98(2):164-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumor].
  • [Transliterated title] Tumore adenomatoide.
  • Adenomatoid tumour is a neoplastic process of discussed origin, but the immunohistochemical phenotype leads a mesothelial derivation.
  • In the present report we described a case of Adenomatoid tumour of the uterus body in a 46 years old patient.
  • [MeSH-major] Adenomatoid Tumor / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Actins / analysis. Calbindin 2. Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques. Keratins / analysis. Leiomyoma / diagnosis. Middle Aged. Neoplasm Proteins / analysis. S100 Calcium Binding Protein G / analysis. Staining and Labeling

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929792.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Actins; 0 / Calbindin 2; 0 / Neoplasm Proteins; 0 / S100 Calcium Binding Protein G; 68238-35-7 / Keratins
  •  go-up   go-down


17. Bandier PC, Hansen A, Thorelius L: [Adenomatoid tumour of the adrenal gland]. Ugeskr Laeger; 2009 Jan 26;171(5):306-8
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumour of the adrenal gland].
  • [Transliterated title] Adenomatoid tumor i binyre.
  • An adenomatoid tumour in the right suprarenal gland was discovered during clinical cancer staging of a 73-year-old woman.
  • Adenomatoid tumours in the suprarenal glands are rare and are most often found incidentally.
  • Differential diagnoses comprise malignant vascular neoplasm or adenocarcinoma.
  • Immunohistochemistry or electron microscopy allows uncomplicated distinction between these tumours.
  • [MeSH-major] Adenomatoid Tumor / pathology. Adrenal Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ugeskr Laeger. 2009 Mar 16;171(12):1015; author reply 1015 [19306484.001]
  • (PMID = 19176156.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


18. Takeda M, Kasai T, Enomoto Y, Takano M, Morita K, Kadota E, Nonomura A: 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. Pathol Int; 2010 May;60(5):395-9
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis.
  • Homozygous deletion of 9p21, the locus harboring the p16 gene, has been reported as one of the most common genetic alterations in malignant mesotheliomas (MMs).
  • Previous studies showed that this alteration might be useful for differentiating benign from malignant mesothelial tumors in cytology and surgical specimens.
  • The purpose of this study is to evaluate the diagnostic utility of 9p21 homozygous deletion assessed by FISH in mesothelial neoplasm and hyperplasia of Japanese patients using paraffin-embedded tissue.
  • In contrast, no cases of adenomatoid tumor, benign mesothelial multicystic tumor, reactive mesothelial hyperplasia or pleuritis showed 9p21 deletion (P < 0.005).
  • 9p21 homozygous deletion correlated well with p16 protein expression in the tumor cells.
  • Our study suggests that 9p21 homozygous deletion assessed by FISH on paraffin-embedded tissue may be very useful for differentiating MM from reactive mesothelial proliferation.
  • [MeSH-major] Chromosomes, Human, Pair 9. Genes, p16. Heart Neoplasms / diagnosis. In Situ Hybridization, Fluorescence / methods. Mesothelioma / diagnosis. Peritoneal Neoplasms / diagnosis. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. DNA, Neoplasm / analysis. Epithelium / pathology. Female. Gene Deletion. Gene Dosage. Humans. Pericardium / metabolism. Pericardium / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518890.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


19. Davidson B, Dong HP, Holth A, Berner A, Risberg B: Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells. Am J Clin Pathol; 2007 May;127(5):752-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells.
  • We studied chemokine receptor expression in malignant mesothelioma (MM), reactive mesothelium (RM), and leukocytes in effusions.
  • Chemokine receptors are widely expressed on leukocytes in MM and RM effusions but are infrequently found on cells of mesothelial origin.
  • This finding suggests a major role for an autocrine chemokine pathway in leukocytes but not in MM cells.
  • The increased monocyte infiltration and their higher chemokine receptor expression in MM effusions may have a tumor-promoting rather than tumor-inhibiting effect.
  • [MeSH-major] Epithelial Cells / immunology. Leukocytes / immunology. Mesothelioma / immunology. Receptors, Chemokine / analysis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17439834.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, CXCR4; 0 / Receptors, Chemokine; 0 / Receptors, Interleukin-8A
  •  go-up   go-down


20. Rehnberg J, Zendehrokh N, Dejmek A: Lower proliferation rate in metastatic effusion mesothelial cells than in benign effusions. Anal Quant Cytol Histol; 2007 Aug;29(4):217-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lower proliferation rate in metastatic effusion mesothelial cells than in benign effusions.
  • OBJECTIVE: To determine the proliferation rates of mesothelial cells in metastatic and benign effusions.
  • STUDY DESIGN: Immunohistochemistry was performed on formalin-fixed pellets from 16 malignant and 9 benign clinical effusions.
  • Dual staining with antibodies against Ki-67 (MIB-1) and desmin was applied to all effusions to differentiate between benign mesothelial cells and malignant cells, and the proportions of desmin+/Ki-67+ and desmin+/Ki-67- cells were calculated.
  • RESULTS: In 7 malignant effusions no proliferating mesothelial cells were found, whereas some rate of proliferation could always be demonstrated in mesothelial cells in the benign effusions.
  • Further, the median proportions of proliferating cells, malignant 2% vs. benign 11%, differed significantly.
  • CONCLUSIONS: To our knowledge this finding has not been previously described, and it may have implications for both cytologic diagnosis and the understanding of tumor biology and the interaction between tumor cells and mesothelial cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17879629.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Desmin; 0 / Ki-67 Antigen
  •  go-up   go-down


21. Minato H, Nojima T, Kurose N, Kinoshita E: Adenomatoid tumor of the pleura. Pathol Int; 2009 Aug;59(8):567-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatoid tumor of the pleura.
  • A case of adenomatoid tumor of the pleura is reported, and its differential diagnosis from benign and malignant pleural lesions is discussed.
  • A 7 mm, circumscribed tumor had characteristic features of adenomatoid tumor.
  • The tumor was composed of an aggregation of irregularly shaped tubulocystic spaces with fibrous stoma.
  • On immunohistochemistry the tumor cells were positive for AE1/AE3, CAM5.2, vimentin, cytokeratin 5/6, D2-40, calretinin, thrombomodulin, and WT-1, but negative for CEA, Leu M1 (CD15), thyroid transcription factor-1, epithelial membrane antigen, desmin, glucose transporter-1 (GLUT-1), CD31, and CD34.
  • Adenomatoid tumor of the pleura is rare, and the pathogenesis has not been elucidated.
  • Recognition of these benign mesothelial lesions in the pleura is important to avoid misdiagnosis.
  • The immunohistochemistry in the present case supports its mesothelial origin.
  • [MeSH-major] Adenomatoid Tumor / pathology. Neoplasms, Multiple Primary / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Dermatomyositis / complications. Esophageal Neoplasms / complications. Esophageal Neoplasms / pathology. Female. Humans. Immunohistochemistry. Incidental Findings. Liver Cirrhosis, Biliary / complications. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19627540.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


22. Ghossain MA, Chucrallah A, Kanso H, Aoun NJ, Abboud J: Multilocular adenomatoid tumor of the ovary: ultrasonographic findings. J Clin Ultrasound; 2005 Jun;33(5):233-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multilocular adenomatoid tumor of the ovary: ultrasonographic findings.
  • We report the sonographic findings of a rare benign ovarian tumor in a 69-year-old woman.
  • Surgery revealed an adenomatoid tumor.
  • Adenomatoid tumors are benign lesions of mesothelial origin, usually solid in nature and rarely located in the ovaries. (c) 2005 Wiley Periodicals, Inc.
  • [MeSH-major] Adenomatoid Tumor / ultrasonography. Ovarian Neoplasms / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley Periodicals, Inc. J Clin Ultrasound 33:233-236, 2005.
  • (PMID = 16047378.001).
  • [ISSN] 0091-2751
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Davidson B, Baekelandt M, Shih IeM: MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. Diagn Cytopathol; 2007 Dec;35(12):756-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells.
  • Using gene expression arrays, we recently showed that MUC4 expression is significantly higher in ovarian/primary peritoneal serous carcinoma (OC/PPC) compared to diffuse peritoneal malignant mesothelioma (DMPM).
  • We additionally studied the ability of MUC4 to differentiate between OC/PPC and reactive mesothelial cells (RMC).
  • OC/PPC effusions (n = 142) and benign reactive effusions (n = 10) were immunostained for MUC4 expression.
  • Immunoreactivity was scored in carcinoma cells and RMC and was compared with tumor cell expression in 60 previously studied primary carcinomas and solid metastases and analyzed for association with clinicopathologic parameters, including survival.
  • Higher MUC4 expression was seen in tumors from older (>60 year) patients (P = 0.049).
  • The data in the present study, together with our earlier report, show that MUC4 is an excellent marker for differentiating OC/PPC from both benign and malignant mesothelial cells.
  • [MeSH-major] Ascitic Fluid / metabolism. Cystadenocarcinoma, Serous / metabolism. Mesothelioma / metabolism. Mucins / biosynthesis. Ovarian Neoplasms / metabolism. Pleural Effusion, Malignant / metabolism
  • [MeSH-minor] Age Factors. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Mucin-4. Oligonucleotide Array Sequence Analysis. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / pathology. Up-Regulation

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 18008338.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC4 protein, human; 0 / Mucin-4; 0 / Mucins
  •  go-up   go-down


24. Deniz H, Kibar Y, Güldür ME, Bakir K: Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations? Pathol Res Pract; 2009;205(11):749-52
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
  • Since pulmonary adenocarcinomas, malignant mesotheliomas (MM), and sometimes benign mesothelial proliferations show a great histomorphological resemblance to each other, an immunohistochemical panel is usually necessary for differential diagnosis.
  • It has also been suggested to be useful in identifying the mesothelial differentiation.
  • The aim of this study is to compare D2-40 immunostaining in MM, pulmonary adenocarcinoma, and benign mesothelial proliferations.
  • In this retrospective study, D2-40 immunostaining was investigated in 37 cases of MM, 36 cases of pulmonary adenocarcinoma, and 31 cases of benign mesothelial proliferation.
  • Predominantly membranous immunoreactivity was observed in 51% of MMs and in 55% of benign mesothelial proliferations.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antibodies, Monoclonal. Lung / metabolism. Lung Neoplasms / diagnosis. Mesothelioma / diagnosis. Solitary Fibrous Tumor, Pleural / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Biomarkers, Tumor / metabolism. Chi-Square Distribution. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Pleura / metabolism. Pleural Neoplasms / diagnosis. Pleural Neoplasms / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19573998.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / monoclonal antibody D2-40
  •  go-up   go-down


25. Llarena Ibarguren R, Rodríguez JG, Olano Grasa I, Azurmendi Arín I, Cantón Aller E, Pertusa Peña C: [Adenomatoid tumor of the epididymis. Report of five cases]. Arch Esp Urol; 2008 Sep;61(7):831-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumor of the epididymis. Report of five cases].
  • [Transliterated title] Tumor adenomatoide epididimario. Aportación de 5 casos.
  • OBJECTIVE: Adenomatoid tumor of the epididymis is unfrequent, benign, with no malignant outcomes described.
  • METHODS: We report five cases, with patient's ages varying from 31 to 76 years, and tumor sizes from 6 to 30 mm.
  • Pathology confirmed the benign adenomatoid character in all cases.
  • CONCLUSIONS: Despite the clinical, ultrasound and physical examination findings suggest the localization in the epididymis and its benign character, surgical exploration is mandatory with surgical excision of the paratesticular mass.
  • [MeSH-major] Adenomatoid Tumor. Epididymis. Genital Neoplasms, Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18972922.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


26. Yeh CJ, Chuang WY, Chou HH, Jung SM, Hsueh S: Multiple extragenital adenomatoid tumors in the mesocolon and omentum. APMIS; 2008 Nov;116(11):1016-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple extragenital adenomatoid tumors in the mesocolon and omentum.
  • Adenomatoid tumors are benign mesothelial neoplasms most commonly found in the male and female genital tracts.
  • Extragenital adenomatoid tumors are rare, most of them being solitary tumors.
  • To our knowledge, only one case of multiple extragenital adenomatoid tumors, involving the liver and peritoneum, has been reported to date.
  • Here we report another case of multiple extragenital adenomatoid tumors involving the mesocolon and omentum.
  • The patient was transferred to our hospital without resection due to the intraoperative finding of multiple peritoneal tumors.
  • At our hospital, an 8.0x7.5x6.0 cm tumor at the mesocolon of the sigmoid colon and three omental nodules measuring up to 2.5x2.0x1.7 cm were resected.
  • Immunohistochemically, the tumor cells were positive for pan-cytokeratin AE1/AE3, vimentin, cytokeratin 5/6 and calretinin.
  • Despite their rarity, adenomatoid tumors should be included in the differential diagnosis of multiple intra-abdominal tumors.
  • [MeSH-major] Adenomatoid Tumor / pathology. Mesocolon / pathology. Neoplasms, Multiple Primary / pathology. Omentum / pathology. Peritoneal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19133002.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


27. Wu M, Sun Y, Li G, Desman G, Wang B, Gil J, Burstein DE: Immunohistochemical detection of XIAP in mesothelium and mesothelial lesions. Am J Clin Pathol; 2007 Nov;128(5):783-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of XIAP in mesothelium and mesothelial lesions.
  • We examined benign and malignant mesothelial tissue samples for the presence of X-linked inhibitor of apoptosis protein (XIAP), a potent constituent of the inhibitor of apoptosis family of caspase inhibitors.
  • We subjected 55 sections (31 malignant mesotheliomas, 2 well-differentiated peritoneal mesotheliomas, 13 pleural mesothelial hyperplasias, and 9 benign mesothelial tissues) from archival formalin-fixed, paraffin-embedded surgical tissue blocks to citrate-based antigen retrieval and then incubated them with monoclonal anti-XIAP (clone 48, dilution 1:250; BD Biosciences, San Jose, CA) at 4 degrees C for 72 hours and developed them using EnVision-Plus reagents (DAKO, Carpinteria, CA) and diaminobenzidine as the chromogen.
  • All 9 normal mesothelial samples were negative for XIAP.
  • Of 13 mesothelial hyperplasias, 1 (8%) was weakly positive in fewer than 10% of cells, as was 1 of 2 well-differentiated peritoneal mesotheliomas.
  • Of 31 malignant mesotheliomas, 25 (81%) displayed XIAP positivity.
  • XIAP immunostaining, when strong, allows for distinction of malignant from benign and hyperplastic mesothelial cell populations and is a potentially useful immunodiagnostic marker in small samples and morphologically controversial cases.
  • Elevated expression of XIAP could contribute to tumorigenesis in mesothelioma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Epithelium / chemistry. Immunohistochemistry / methods. Mesothelioma / chemistry. Peritoneal Neoplasms / chemistry. Precancerous Conditions / chemistry. X-Linked Inhibitor of Apoptosis Protein / analysis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17951200.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human
  •  go-up   go-down


28. Kachali C, Eltoum I, Horton D, Chhieng DC: Use of mesothelin as a marker for mesothelial cells in cytologic specimens. Semin Diagn Pathol; 2006 Feb;23(1):20-4
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of mesothelin as a marker for mesothelial cells in cytologic specimens.
  • Immunocytochemistry is often employed for the distinction between mesothelial cells and adenocarcinoma.
  • Mesothelin has recently been reported to be expressed in reactive mesothelial cells and epithelioid mesotheliomas.
  • The objective of this study is to determine the utility of mesothelin as marker for mesothelial cells in cytologic preparations.
  • Nine were benign effusions, 11 mesotheliomas, and 18 metastatic adenocarcinomas.
  • Mesothelin staining was positive in 7/9 benign cases, 8/11 mesotheliomas, and 8/18 adenocarcinomas.
  • The difference of mesothelin expression between mesothelial cells and adenocarcinoma was statistically significant.
  • For calretinin, all cases, except 2 malignant mesotheliomas and 3 adenocarcinomas, showed positive staining with calretinin.
  • As a marker for mesothelial cells, the sensitivity and specificity of mesothelin were 73% and 55%, respectively, and the sensitivity and specificity of calretinin were 95% and 86%, respectively.
  • Therefore, mesothelin is not a sensitive or a specific marker for mesothelial cells in cytologic specimens when compared with calretinin.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Membrane Glycoproteins / metabolism. Mesothelioma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17044192.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / S100 Calcium Binding Protein G; 0 / mesothelin
  •  go-up   go-down


29. Szczepulska-Wójcik E, Langfort R, Roszkowski-Sliz K: [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation]. Pneumonol Alergol Pol; 2007;75(1):57-69
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
  • INTRODUCTION: Histopathological diagnosis of malignant mesothelioma (MM) and differentiating it from tumors infiltrating the pleura is very difficult.
  • Distinguishing benign reactive mesothelial cell proliferation from MM also presents problems.
  • The objective of this study was to evaluate the significance of selected immunohistochemical stains in differentiating MM from non-small cell lung cancers infiltrating the pleura and from benign reactive mesothelial cell proliferation.
  • MATERIAL AND METHODS: The material encompassed 86 cases of MM, 54 cases of NSCLC infiltrating the pleura, and 43 cases of benign reactive mesothelial cell proliferation.
  • It included broad-spectrum antibodies to cytokeratins (CKAE1/AE3, CKMNF116), vimentin, epithelial membrane antigen (EMA), mesothelial cells (HBME1, CK5/6, calretinin), adenocarcinoma cells (BerEp4, B72.3, CEA, TTF1), antibodies enabling the assessment of proliferation (Mib1) and cell-cycle regulating proteins (p53).
  • Benign reactive mesothelial cell proliferation: Protein p53 was present in 9.3% of cases, whereas no positive staining for EMA was found.
  • CONCLUSION: In diagnosing mesothelioma it is necessary to use a panel of immunohistochemical stains, which should contain antibodies to markers for adenocarcinoma and mesothelioma.
  • In the diagnosis of spindle-cell pleural tumors and the fibrous form of MM and benign reactive mesothelial cell proliferation , markers of mesothelial cells are noncontributory.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / analysis. Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / pathology. Mesothelioma / pathology. Neoplasm Proteins / analysis. Neoplasms, Mesothelial / pathology. Pleural Neoplasms / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17541913.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


30. Asghar S, Qureshi N, Awan A: Benign mesothelioma of peritoneum presenting as a pelvic mass. J Coll Physicians Surg Pak; 2008 Nov;18(11):723-5
MedlinePlus Health Information. consumer health - Pelvic Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign mesothelioma of peritoneum presenting as a pelvic mass.
  • A large solitary multiloculated pelvic cyst in a 40-year-old woman with chronic pelvic pain was diagnosed to be a Multicystic Benign Mesothelioma (MBM) of peritoneum at laparotomy.
  • [MeSH-major] Mesothelioma, Cystic / diagnosis. Ovarian Neoplasms / diagnosis. Pelvic Neoplasms / diagnosis. Pelvic Pain / diagnosis. Peritoneal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18983801.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


31. Burel-Vandenbos F, Cardot-Leccia N, Effi B, Varini JP, Saint-Paul MC, Michiels JF: [An unusual tumor of the adrenal gland]. Ann Pathol; 2005 Oct;25(5):386-8
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An unusual tumor of the adrenal gland].
  • [Transliterated title] Une tumeur inhabituelle de la surrénale.
  • Adenomatoid tumors are benign mesothelial tumors that usually affect the genital tract.
  • We report the case of a 65-year-old man with an adenomatoid tumor of the adrenal gland.
  • This uncommon location and its histological heterogeneity can lead to a mistaken diagnosis of malignant tumor.
  • Positive cells with mesothelial markers in immunohistochemistry improve diagnosis.
  • The proper identification of this benign tumor in the adrenal gland and the knowledge of its differential diagnosis deserve attention to avoid invasive treatment.
  • [MeSH-major] Adenomatoid Tumor / pathology. Adrenal Gland Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adrenalectomy. Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Lymphangioma / diagnosis. Male. Neoplasm Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498291.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


32. Duval H, Rioux-Leclercq N, Bauville E, Al Jaradi M, Burtin F: [Multinodular-adenomatoid tumor of the uterus in a patient with a renal allograft]. Ann Pathol; 2008 Sep;28(4):308-10
HAL archives ouvertes. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multinodular-adenomatoid tumor of the uterus in a patient with a renal allograft].
  • [Transliterated title] Tumeur adénomatoïde multinodulaire de l'utérus chez une patiente avec allogreffe rénale.
  • A case of diffuse-adenomatoid tumor of the uterus occurring in a 43-year-old patient with a renal-allograft transplant is reported.
  • The diagnosis was supported by the adenomatoid and angiomatoid histologic patterns and the mesothelial immunophenotype.
  • Diffuse-adenomatoid tumor of the uterus is a rare and benign lesion, usually reported in patients with immunodeficiency and renal transplant.

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18928872.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G
  •  go-up   go-down


33. Moyano Calvo JL, Giraldez Puig J, Sánchez de la Vega J, Dávalos Casanova G, Morales López A: [Adenomatoid tumor of the epididymis]. Actas Urol Esp; 2007 Apr;31(4):417-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumor of the epididymis].
  • [Transliterated title] Tumor adenomatoide de epididimo.
  • OBJECTIVE: Paratesticular tumors are very rare and mostly bening.
  • Wa aport a new case of adenomatoid tumor of epididymis METHOD: Male of 40 years old with solid lesion in epidididymis tale treated with mass exéresis RESULTS: Adenoamotid tumor of the epididymis confirmed with hystopathologic technique CONCLUSION: Adenomatoid tumor of epididymis is the most frequent paratesticular tumors and when is suspected, conservative surgery must be performed.
  • [MeSH-major] Adenomatoid Tumor. Epididymis. Genital Neoplasms, Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633930.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


34. González Resina R, Carranza Carranza A, Congregado Córdoba J, Conde Sánchez JM, Congregado Ruiz CB, Medina López R: [Paratesticular adenomatoid tumor: a report of nine cases]. Actas Urol Esp; 2010 Jan;34(1):95-100

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Paratesticular adenomatoid tumor: a report of nine cases].
  • [Transliterated title] Tumor adenomatoide paratesticular: una serie de nueve casos.
  • INTRODUCTION: Paratesticular tumors are rare.
  • Most of them are benign, and adenomatoid tumors are most common.
  • These tumors sometimes infiltrate the testicular parenchyma and require differential diagnosis with malignant tumors.
  • MATERIALS AND METHODS: A retrospective study of nine patients with paratesticular adenomatoid tumors seen during a nine-year period (2000-2008) is reported.
  • The tumor most commonly occurred as a small, usually oval, nodule in the tail of epididymis.
  • Our series included a case each of intraparenchymal tumor of the testis and tumor of the tunica vaginalis.
  • [MeSH-major] Adenomatoid Tumor / pathology. Epididymis / pathology. Genital Neoplasms, Male / pathology
  • [MeSH-minor] Adult. Calbindin 2. Diagnosis, Differential. Humans. Keratins / analysis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Proteins / analysis. Retrospective Studies. S100 Calcium Binding Protein G / analysis. Testis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20223139.001).
  • [ISSN] 1699-7980
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Calbindin 2; 0 / Neoplasm Proteins; 0 / S100 Calcium Binding Protein G; 68238-35-7 / Keratins
  • [Number-of-references] 13
  •  go-up   go-down


35. Politi E, Kandaraki C, Apostolopoulou C, Kyritsi T, Koutselini H: Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Diagn Cytopathol; 2005 Mar;32(3):151-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
  • The morphological evaluation of cytological specimens from body cavity fluids presents difficulties in the differential diagnosis between benign reactive mesothelial (RM) cells and adenocarcinoma (AC) or malignant mesothelioma (MM).
  • A total of 134 cytological specimens of serous effusions from 80 ACs, 50 RMs, and 4 MMs, previously stained with Papanicolaou stain, were selected retrospectively from our files and stained with anti-human mesothelial cell (HBME-1), calretinin, epithelial specific antigen (MOC-31), Ber-EP4, and BG8.
  • Statistical significance was found with HBME-1, calretinin, MOC-31, anti-human epithelial antigen (Ber-EP4), and blood group related antigen (BG8) when comparing AC vs. any type of mesothelial proliferation (MM or RM).
  • The sensitivity of HBME-1 and calretinin for mesothelial cells was 98 and 100%, respectively, and the specificity was 71 and 80%, respectively.
  • Both antibodies stained reactive mesothelial as well as MM cells, with calretinin showing a stronger intensity of immunostaining.
  • Our data suggest that immunocytochemical studies performed on Papanicolaou-stained cytological smears with HBME-1, calretinin, MOC-31, Ber-EP4, and BG8 proved to be useful in the differentiation between metastatic AC and mesothelial proliferation.
  • Probably, calretinin is a more preferred marker for mesothelial cells as evidenced by a more intense staining reaction.
  • [MeSH-major] Adenocarcinoma / diagnosis. Ascitic Fluid / pathology. Biomarkers, Tumor / metabolism. Mesothelioma / diagnosis. Pericardial Effusion / pathology. Pleural Effusion / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Immunohistochemistry. Middle Aged

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15690338.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


36. Kalyani R, Das S: Adenomatatoid tumor: Cytological diagnosis of two cases. J Cytol; 2009 Jan;26(1):30-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatatoid tumor: Cytological diagnosis of two cases.
  • Adenomatoid tumor is a benign neoplasm of mesothelial cell origin that occurs in both male and female genital tracts.
  • Fine needle aspiration cytology has an important role in the preoperative diagnosis of the male genital adenomatoid tumor and is a rapid, reliable, conclusive, and cost-effective diagnostic tool that can be used to take appropriate surgical decisions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Cytol. 1999 May-Jun;43(3):495-7 [10349389.001]
  • [Cites] BJU Int. 2005 Jul;96(1):67-9 [15963123.001]
  • [Cites] Acta Cytol. 1989 Jan-Feb;33(1):6-10 [2916372.001]
  • [Cites] J Urol. 1995 Nov;154(5):1756-8 [7563340.001]
  • [Cites] Acta Cytol. 1998 Nov-Dec;42(6):1458-60 [9850662.001]
  • [Cites] AJR Am J Roentgenol. 1983 Mar;140(3):511-5 [6600544.001]
  • [Cites] J Urol. 1988 Apr;139(4):819-20 [3352056.001]
  • (PMID = 21938146.001).
  • [ISSN] 0970-9371
  • [Journal-full-title] Journal of cytology
  • [ISO-abbreviation] J Cytol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3167987
  • [Keywords] NOTNLM ; Adenomatoid tumor / FNAC / epididymis / testis
  •  go-up   go-down


37. Kim JH, Kim GE, Choi YD, Lee JS, Lee JH, Nam JH, Choi C: Immunocytochemical panel for distinguishing between adenocarcinomas and reactive mesothelial cells in effusion cell blocks. Diagn Cytopathol; 2009 Apr;37(4):258-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunocytochemical panel for distinguishing between adenocarcinomas and reactive mesothelial cells in effusion cell blocks.
  • The aim of our study was to determine the value of a panel that consisted of one epithelial marker (MOC-31) and two mesothelial markers (D2-40 and calretinin) for distinguishing between reactive mesothelial cells (RMCs) and adenocarcinomas (ACs) in effusion fluids.
  • A total of 118 cell block specimens from pleural and peritoneal effusions, including 88 ACs and 30 benign effusions with RMCs were stained with antibodies against MOC-31, D2-40, and calretinin.
  • MOC-31 membranous activity was observed in all samples from ACs, regardless of the primary tumor site.
  • All benign effusion samples with RMCs were negative for MOC-31.
  • All benign effusion samples with RMCs exhibited membranous staining for D2-40, and one AC case had focal reactivity for D2-40.
  • Almost all benign effusions reacted positively with calretinin.
  • Scattered tumor cells had weak calretinin positivity in two AC cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19217030.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Garrido Abad P, Jiménez Gálvez M, Herranz Fernández LM, Bocardo Fajardo G, Arellano Gañán R, Pereira Sanz I: [Adenomatoid tumor of the epididymis. Report of two cases]. Arch Esp Urol; 2007 Jul-Aug;60(6):700-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumor of the epididymis. Report of two cases].
  • [Transliterated title] Tumor adenomatoide de epidídimo. Aportación de dos casos.
  • OBJECTIVE: Tumors of the epididymis are rare.
  • They are unusually benign and adenomatoid tumors are the most frequent.
  • Report of two cases of this kind of tumor of the epididymis.
  • METHODS/RESULTS: We report two cases of adenomatoid tumor of the epididymis diagnosed at our hospital during last year.
  • Pathological diagnosis was adenomatoid tumor.
  • CONCLUSIONS: The majority of epididymal tumors follow a benign course.
  • In the finding of an epididymal mass, after palpation and imaging tests, organ sparing surgery (epididymectomy) is recommended.
  • [MeSH-major] Adenomatoid Tumor. Epididymis. Genital Neoplasms, Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17847749.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


39. Okamoto S, Ito K, Sasano H, Moriya T, Niikura H, Terada Y, Sato S, Okamura K, Yaegashi N: Ber-EP4 and anti-calretinin antibodies: a useful combination for differential diagnosis of various histological types of ovarian cancer cells and mesothelial cells. Tohoku J Exp Med; 2005 May;206(1):31-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ber-EP4 and anti-calretinin antibodies: a useful combination for differential diagnosis of various histological types of ovarian cancer cells and mesothelial cells.
  • The differential diagnosis between reactive mesothelial cells and ovarian carcinoma cells is often difficult in cytologic specimens.
  • Therefore, we evaluated the practical value of various epithelial and mesothelial markers in differential diagnosis of these two types of cells.
  • Various types of ovarian carcinoma (serous, n = 22; mucinous, n = 10; endometrioid, n = 7; clear cell, n = 10) and benign mesothelial tissues (n = 15) were studied by immunohistochemistry.
  • We then studied effective panels of antibodies by immunohistochemistry in 43 cytologic specimens of ascites or peritoneal lavage fluid consisting of 20 reactive mesothelium and 23 adenocarcinomas of the ovary.
  • In the tissue specimens, Ber-EP4, a monoclonal antibody of epithelial antigen, and a polyclonal antibody against calretinin, which is expressed in mesothelium, are used in differentiating reactive mesothelial cells from ovarian carcinoma.
  • Using multiple regression analysis, the correlation coefficient between epithelial antigen and calretinin reactivity was r = 0.938, with a significance level of p < 0.0001.
  • In conclusion, the combined immunostaining of cytologic specimens for Ber-EP4 and the anti-calretinin antibody is helpful for the differential diagnosis between mesothelial cells and not only serous type, but also mucinous, endometrioid and clear cell types of ovarian cancer cells.
  • [MeSH-major] Antibodies. Biomarkers, Tumor / immunology. Epithelium / immunology. Ovarian Neoplasms / diagnosis. S100 Calcium Binding Protein G / immunology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15802873.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 0 / human epithelial antigen-125
  •  go-up   go-down


40. Kilic N, Tilki D, Ergün B, Seitz M, Stief CG, Reich O, Ergün S: Epithelial versus endothelial CEACAM1 expression and angiogenesis in epididymal adenomatoid tumor. Anticancer Res; 2010 Jul;30(7):2651-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial versus endothelial CEACAM1 expression and angiogenesis in epididymal adenomatoid tumor.
  • BACKGROUND/AIM: To study the expression of the pro-angiogenic factor carcinoembryonic antigen-related cell adhesion molecule-1 (CEACAM1) in epididymal adeno-matoid tumor tissue, a very rare benign neoplasia, in relation to its vascularization.
  • MATERIALS AND METHODS: Immunohistochemistry for CEACAM1 and for both endothelial markers CD31 and CD34 was performed in normal human epididymal and epididymal adenomatoid tumor tissue.
  • The vessel density was calculated in four tumor regions with different degrees of vascularization in comparison to the vascularization of the normal epididymal tissue.
  • RESULTS: CEACAM1 was found in normal epididymal epithelium, while the epithelium of tumor glands was mostly negative.
  • Only few blood vessels and lymphatics in adenomatoid tumor tissue expressed CEACAM1.
  • The assessment of vascularization revealed either equal or a significantly lower vessel density in some adenomatoid tumor regions in comparison to normal epididymal tissue.
  • DISCUSSION: These data demonstrate that despite its epithelial down-regulation, CEACAM1 is not present in the majority of adenomatoid tumor blood vessels, which might be related to the lower angiogenic activity and benign behaviour of this tumor.
  • [MeSH-major] Adenomatoid Tumor / blood supply. Antigens, CD / biosynthesis. Cell Adhesion Molecules / biosynthesis. Testicular Neoplasms / blood supply
  • [MeSH-minor] Antigens, CD31 / biosynthesis. Antigens, CD34 / biosynthesis. Endothelial Cells / metabolism. Epididymis / blood supply. Epididymis / metabolism. Epithelial Cells / metabolism. Humans. Immunohistochemistry. Male. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20682994.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD31; 0 / Antigens, CD34; 0 / CD66 antigens; 0 / Cell Adhesion Molecules
  •  go-up   go-down


41. Torregrossa L, Faviana P, Filice ME, Materazzi G, Miccoli P, Vitti P, Fontanini G, Melillo RM, Santoro M, Basolo F: CXC chemokine receptor 4 immunodetection in the follicular variant of papillary thyroid carcinoma: comparison to galectin-3 and hector battifora mesothelial cell-1. Thyroid; 2010 May;20(5):495-504
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXC chemokine receptor 4 immunodetection in the follicular variant of papillary thyroid carcinoma: comparison to galectin-3 and hector battifora mesothelial cell-1.
  • BACKGROUND: The cytological discrimination between benign and malignant follicular-patterned lesions of the thyroid can represent a diagnostic challenge, even for experienced pathologists.
  • We evaluated the diagnostic use of protein expression of CXC chemokine receptor 4 (CXCR4) and galectin-3 (gal-3) that were found to be upregulated in papillary thyroid carcinoma compared to normal thyroid and of mesothelial cell surface protein recognized by monoclonal antibody Hector Battifora Mesothelial cell (HBME)-1 in thyroid tumors.
  • METHODS: Expression of CXCR4, HBME-1, and gal-3 was examined immunohistochemically in total of 100 aspirates of thyroid lesions, categorized as benign (n = 22), indeterminate lesion (n = 43), suspicious of papillary thyroid carcinoma (n = 10), or malignant (n = 25) by preoperative cytology.
  • CONCLUSIONS: An immunohistochemical panel, including CXCR4, could be useful in the differential diagnosis between benign and malignant well-differentiated follicular-patterned thyroid lesions.
  • [MeSH-major] Biomarkers, Tumor / chemistry. Carcinoma, Papillary, Follicular / chemistry. Galectin 3 / chemistry. Receptors, CXCR4 / chemistry. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450430.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / HBME-1 antigen; 0 / Receptors, CXCR4
  •  go-up   go-down


42. Hasteh F, Lin GY, Weidner N, Michael CW: The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. Cancer Cytopathol; 2010 Apr 25;118(2):90-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.
  • BACKGROUND: The distinction of benign from malignant mesothelial proliferations in cytologic specimens can be problematic.
  • METHODS: Archival paraffin-embedded cell blocks of pleural and peritoneal fluids from 52 patients with malignant mesothelioma (MM) and 64 patients with reactive mesothelial hyperplasia (MH) were retrieved.
  • IHC stains included desmin, epithelial membrane antigen (EMA), glucose-transport protein 1 (GLUT-1), Ki67, and p53.
  • EMA was positive in 9% (6 of 64) of benign and 100% (52 of 52) of malignant cases (P < .001).
  • GLUT-1 was positive in 12% (5 of 43) of benign and 47% (7 of 15) of malignant cases.
  • Ki67 showed strong nuclear positivity in >40% of mesothelial cells in 9% (6 of 64) of benign and 16% (8 of 49) of malignant cases (P = .38).
  • p53 showed strong nuclear positivity in 2% (1 of 46) of benign and 47% (7 of 15) of malignant cases (P < .001).
  • Likewise, strong membranous positivity for GLUT-1 and/or strong nuclear staining for p53 favors a mesothelioma.
  • [MeSH-major] Ascitic Fluid / metabolism. Epithelium / pathology. Immunohistochemistry. Mesothelioma / diagnosis. Pleural Effusion / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / metabolism. Desmin / analysis. Excitatory Amino Acid Transporter 2 / analysis. Female. Humans. Hyperplasia / pathology. Male. Middle Aged. Mucin-1 / analysis. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 American Cancer Society.
  • [CommentIn] Cancer Cytopathol. 2010 Aug 25;118(4):225; author reply 225 [20731007.001]
  • (PMID = 20209622.001).
  • [ISSN] 1934-662X
  • [Journal-full-title] Cancer cytopathology
  • [ISO-abbreviation] Cancer Cytopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Desmin; 0 / Excitatory Amino Acid Transporter 2; 0 / Mucin-1; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


43. Bisceglia M, Carosi I, Scillitani A, Pasquinelli G: Cystic lymphangioma-like adenomatoid tumor of the adrenal gland: Case presentation and review of the literature. Adv Anat Pathol; 2009 Nov;16(6):424-32
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for adenomatoid tumor .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic lymphangioma-like adenomatoid tumor of the adrenal gland: Case presentation and review of the literature.
  • Adenomatoid tumors (AT) are usually found in the genital tract of both sexes.
  • Thirty-four cases have been reported so far, more often presenting grossly as solid tumors, rarely as solid with cystic areas, and 5 cases were almost entirely cystic.
  • On light microscopy the diagnosis may be very difficult if the tumor is rich in vacuolated cells, mimicking metastatic signet ring-cell adenocarcinoma.
  • Immunophenotyping and/or electron microscopy are paramount in helping to ascertain their mesothelial lineage.
  • Lymphangioma is the main histologic mimic of solid-cystic and cystic AT-AG, but lymphangioma is immunopositive for endothelial markers and negative for cytokeratins and mesothelial markers.
  • The adrenal tumor was 5.5 cm in size and was fully investigated immunohistochemically and ultrastructurally.
  • [MeSH-major] Adenomatoid Tumor / pathology. Adrenal Gland Neoplasms / pathology. Lymphangioma, Cystic / pathology

  • Genetic Alliance. consumer health - Lymphangioma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19851133.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


44. Sharma G, Linden MD, Schultz DS, Inamdar KV: Cystic tumor of the atrioventricular node: an unexpected finding in an explanted heart. Cardiovasc Pathol; 2010 May-Jun;19(3):e75-8
Genetic Alliance. consumer health - Heart tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic tumor of the atrioventricular node: an unexpected finding in an explanted heart.
  • SUMMARY: We report herein a unique case of cystic tumor of atrioventricular (AV) node (CTAVN), which, to our knowledge, is the first of its kind diagnosed in an explanted heart specimen and only the fourth diagnosed antemortem.
  • Often, this rare tumor can only be diagnosed by careful gross examination and adequate sampling of AV node region.
  • CONTEXT: CTAVN is a rare, benign tumor.
  • The patient's history was significant for congenital heart block requiring placement of a permanent pacemaker at 12 years of age.
  • These lesions are now believed to be endodermal in origin, although mesothelial origin was earlier proposed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19144541.001).
  • [ISSN] 1879-1336
  • [Journal-full-title] Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology
  • [ISO-abbreviation] Cardiovasc. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


45. Pinto V, Rossi AC, Fiore MG, D'Addario V, Cicinelli E: Laparoscopic diagnosis and treatment of pelvic benign multicystic mesothelioma associated with high CA19.9 serum concentration. J Minim Invasive Gynecol; 2010 Mar-Apr;17(2):252-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic diagnosis and treatment of pelvic benign multicystic mesothelioma associated with high CA19.9 serum concentration.
  • We report a case of benign multicystic mesothelioma in a 20-year-old woman referred because of amenorrhea.
  • Tumor serum markers revealed an increase in CA19.9.
  • Microscopically, cystic lesions showed mesothelium-lined cystic spaces surrounded by a delicate thin fibrovascular wall.
  • With immunohistochemistry, the tumor cells were strongly positive for cytokeratin and calretinin.
  • These aspects were suggestive of benign multicystic mesothelioma.
  • Electron microscopy confirmed the mesothelial nature of this tumor.
  • The association between benign multicystic mesothelioma and increased CA19.9 serum concentration has been described only once, in a man.
  • To our knowledge, this is the second case of benign multicystic mesothelioma associated with increased CA19.9 serum concentration and the first diagnosed in a woman.
  • In the present case, a minimally invasive laparoscopic approach enabled not only histologic diagnosis of benign multicystic mesothelioma but also its surgical treatment.
  • Although benign multicystic mesothelioma is a rare pathologic entity, it is important that sonologists include it in the differential diagnosis of diseases that manifest with ascites.
  • Furthermore, all surgeons should be aware of the macroscopic and laparoscopic appearance of the lesion, and its generally benign course.
  • [MeSH-major] CA-19-9 Antigen / blood. Laparoscopy. Mesothelioma, Cystic / pathology. Mesothelioma, Cystic / surgery. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AAGL. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20226419.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


46. Rizkalla HF, Higgins M, Kelehan P, O'Herlihy C: Pathological findings associated with the presence of a mirena intrauterine system at hysterectomy. Int J Gynecol Pathol; 2008 Jan;27(1):74-8
Hazardous Substances Data Bank. LEVONORGESTREL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological findings associated with the presence of a mirena intrauterine system at hysterectomy.
  • Thirty hysterectomy specimens contained benign leiomyomata with associated reduced reactivity in the uterine cavity and incomplete suppression of the endometrium.
  • In addition to leiomyomas, 1 specimen had an atypical polypoid adenomyoma and 1 had a benign adenomatoid tumor.


47. Kontos S, Fokitis I, Karakosta A, Koritsiadis G, Mitsios K, Koutsikos S, Koritsiadis S: Adenomatoid tumor of epididymidis: A case report. Cases J; 2008;1(1):206

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatoid tumor of epididymidis: A case report.
  • BACKGROUND: Adenomatoid tumors are regarded as distinctive benign mesothelial neoplasms of the paratesticular region, most commonly occuring at the tail of the epididymidis.Because of its rarity, the clinical and histopathological aspects are discussed.
  • CASE PRESENTATION: We present the case of a 41-year-old patient with an adenomatoid tumour located in the tail of the left epididymis that referred to our department with gradual enlarged intrascrotal mass.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1998 Dec 15;83(12):2437-46 [9874447.001]
  • [Cites] Eur Urol. 1996;30(1):127-8 [8854081.001]
  • [Cites] Urology. 1985 Jun;25(6):653-4 [4012964.001]
  • [Cites] Semin Diagn Pathol. 2000 Nov;17(4):294-306 [11202546.001]
  • [Cites] J Urol. 2005 Aug;174(2):723 [16006963.001]
  • [Cites] Am J Surg Pathol. 2004 Jan;28(1):77-83 [14707867.001]
  • [Cites] Histopathology. 2001 May;38(5):479 [11422488.001]
  • [Cites] Pathol Annu. 1990;25 Pt 2:51-108 [2202966.001]
  • [Cites] Urology. 1975 Nov;6(5):635-41 [1189154.001]
  • (PMID = 18831762.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2566564
  •  go-up   go-down


48. Canedo-Patzi AM, León-Bojorge B, de Ortíz-Hidalgo C: [Adenomatoid tumor of the genital tract. Clinical, pathological and immunohistochemical study in 9 cases]. Gac Med Mex; 2006 Jan-Feb;142(1):59-66
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumor of the genital tract. Clinical, pathological and immunohistochemical study in 9 cases].
  • [Transliterated title] Tumor adenomatoide del aparato genital, Estudio clinicopatológico e inmunohistoquímico de 9 casos.
  • OBJECTIVE: [corrected] Describe the histological andimmunohistochemicalfeatures of nine genital tract adenomatoid tumors.
  • MATERIAL AND METHODS: Nine cases of adenomatoid tumors were collected from the files of the Pathology department at a private hospital (ABC Hospital).
  • Tumors were studied from a histological and inmunohistochemical perspective.
  • Tumors were located in the uterus (seven),fallopian tube (one) and epididymis (one).
  • Tumor size ranged from 0.4 to 5.8 cm.
  • Arrangement of the neoplastic tubules around fascicles of smooth muscle; angiomatoidpattern with a peripheral location, and solid and adenoidpatterns with a central location in the tumor were some of the observed histological features.
  • Immunohistochemically all tumors exhibited strong and diffuse positivity for calretinin and AE1/AE3.
  • Thrombomodulin was positive in all tumors (focal and weak in angiomatoid pattern and diffuse and strong in adenoid and solid patterns).
  • The CK5/6 antibody was positive in seven tumors (diffuse in three and focal in four).
  • Two tumors were negative for this marker.
  • All tumors were negative for CD31.
  • CONCLUSIONS: The immunopheno type of the adenomatoid tumors in our series confirms their mesothelial origin.
  • [MeSH-major] Adenomatoid Tumor / pathology. Epididymis. Fallopian Tube Neoplasms / pathology. Genital Neoplasms, Male / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16548294.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


49. Liu YY, Morreau H, Kievit J, Romijn JA, Carrasco N, Smit JW: Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. Eur J Endocrinol; 2008 Mar;158(3):375-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma.
  • OBJECTIVES: The microscopic distinction between benign and malignant thyroid lesions in clinical practice is still largely based on conventional histology.
  • This study was performed to evaluate the diagnostic value of galectin-3 (Gal-3), Hector Battifora mesothelial-1 (HBME-1), cytokeratin (CK)-19, CBP P300-interacting transactivator with glutamic acid E- and aspartic acid D-rich C-terminal domain (CITED-1), fibronectin (FN)-1, peroxisome proliferator-activated receptor (PPAR)-gamma, and intracellular sodium/iodide symporter (iNIS) immunostaining in a large panel of thyroid neoplasms.
  • METHODS: We used tissue arrays containing 177 thyroid tissues: 100 benign tissues (including normal thyroid, Graves disease, multinodular goiter, and follicular adenoma (FA)) and 77 thyroid carcinomas (including papillary thyroid carcinoma (PTC), follicular thyroid carcinoma, and follicular variant of PTC (FVPTC)).

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18299472.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / CITED1 protein, human; 0 / Fibronectins; 0 / Galectin 3; 0 / HBME-1 antigen; 0 / Keratin-19; 0 / Nuclear Proteins; 0 / PPAR gamma; 0 / Symporters; 0 / Transcription Factors; 0 / sodium-iodide symporter
  •  go-up   go-down


50. Comoglio C, Sansone F, Delsedime L, Campanella A, Ceresa F, Rinaldi M: Mesothelial cyst of the pericardium, absent on earlier computed tomography. Tex Heart Inst J; 2010;37(3):354-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelial cyst of the pericardium, absent on earlier computed tomography.
  • Pericardial cysts are benign intrathoracic lesions that are considered to be congenital.
  • Herein, we describe the case of a 41-year-old man who, over nearly a decade, had undergone frequent hospital admissions for fever and thoracic pain.
  • Due to the cyst's unusual location and the ineffectiveness of medical therapy, we excised the tumor via median sternotomy.
  • Histopathologic examination confirmed that the lesion was a simple mesothelial cyst of the pericardium.
  • We know of no other report of a pericardial cyst that had gone undetected upon earlier computed tomography.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cardiothorac Surg. 2003 Nov;24(5):684-8 [14583298.001]
  • [Cites] Radiology. 1981 Nov;141(2):323-9 [7291553.001]
  • [Cites] J Am Soc Echocardiogr. 1996 Jan-Feb;9(1):108-12 [8679232.001]
  • [Cites] Heart. 2007 Jan;93(1):22 [17170337.001]
  • [Cites] Tex Heart Inst J. 2004;31(3):313-5 [15562856.001]
  • [Cites] Ann Thorac Surg. 2006 Apr;81(4):e11-2 [16564236.001]
  • [Cites] Ann Thorac Surg. 1997 Mar;63(3):845-7 [9066418.001]
  • (PMID = 20548822.001).
  • [ISSN] 1526-6702
  • [Journal-full-title] Texas Heart Institute journal
  • [ISO-abbreviation] Tex Heart Inst J
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2879185
  • [Keywords] NOTNLM ; Dyspnea/etiology / mediastinal cyst/complications/diagnosis/pathology/radiography/surgery/ultrasonography / pericardial effusion/etiology / tomography, X-ray computed / treatment outcome
  •  go-up   go-down


51. Hanley KZ, Facik MS, Bourne PA, Yang Q, Spaulding BO, Bonfiglio TA, Xu H: Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions. Cancer; 2008 Feb 25;114(1):49-56
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
  • BACKGROUND: Immunohistochemistry is helpful in distinguishing metastatic carcinoma from atypical mesothelial cells; however, it is not useful in differentiating atypical mesothelial cells from malignant mesothelial cells.
  • Using a mouse monoclonal antibody (L523S) against KOC, KOC expression was investigated in malignant tumors and reactive mesothelial cells in serous effusions.
  • METHODS: Seventy-six cases with paraffin-embedded pleural, pericardial, and peritoneal serous effusion cell blocks including 60 malignant serous effusions (11 malignant pleural mesotheliomas and 49 metastatic carcinomas) and benign pleural effusions (14 cases with reactive mesothelial cells and 2 cases with atypical cells with uncertain significance) were selected for immunohistochemical analysis with L523S, calretinin, and CK5/6.
  • RESULTS: Immunohistochemical studies showed that positive staining for KOC of variable degrees of intensity was observed in 47 of 60 cases in malignant serous effusions including 10 of 11 mesotheliomas and 36 of 49 metastatic carcinomas.
  • The associated reactive mesothelial cells were negative for KOC but positive for calretinin and CK5/6.
  • All 11 malignant mesotheliomas exhibited positivity for calretinin, and 9 of 11 cases had CK5/6 staining.
  • In addition, 16 cases that were originally diagnosed either as pleural effusions with reactive mesothelial cells (14) or atypical cells with uncertain significance (2) were also tested for KOC expression.
  • Interestingly, 3 of 16 cases exhibited various degrees of positivity for KOC, 2 of which were diagnosed as lung adenocarcinoma with a recurrence after tumor resection and 1 as malignant pleural mesothelioma.
  • CONCLUSIONS: Anti-L523S antibody is a useful marker for the detection of malignant cells in serous effusions and it can have significant utility in differentiating reactive mesothelial cells from malignant mesothelioma and metastatic carcinoma in combination with calretinin and CK5/6 staining.
  • [MeSH-major] Biomarkers, Tumor / analysis. Mesothelioma / diagnosis. Neoplasm Proteins / analysis. Pleural Effusion / diagnosis. Pleural Effusion, Malignant / diagnosis. RNA-Binding Proteins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ascitic Fluid / chemistry. Calbindin 2. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis. Pericardial Effusion / chemistry. S100 Calcium Binding Protein G / analysis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society
  • (PMID = 18098206.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calb2 protein, mouse; 0 / Calbindin 2; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins; 0 / S100 Calcium Binding Protein G
  •  go-up   go-down


52. Dejmek A: CK5/6 in effusions: no difference between mesothelioma and pulmonary and nonpulmonary adenocarcinoma. Acta Cytol; 2008 Sep-Oct;52(5):579-83
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CK5/6 in effusions: no difference between mesothelioma and pulmonary and nonpulmonary adenocarcinoma.
  • OBJECTIVE: To test the performance of CK5/6 for the differentiation between mesothelioma, adenocarcinoma and benign mesothelia/proliferations in effusion cytology.
  • STUDY DESIGN: CKS/6 immunocytochemistry was applied to ethanol-fixed cytospin preparations from 74 benign and malignant effusions.
  • RESULTS: Reactivity was seen in 7 of 8 mesotheliomas and in 9 of 11 benign mesothelial proliferations but also in 11 of l7 pulmonary adenocarcinomas and in 12 of 31 adenocarcinomas of nonpulmonary origin.
  • The high reactivity rate in pulmonary adenocarcinomas disagrees with the results obtained with histologic sections from solid tumor tissue, and CK5/6 seems to be of very limited value as an additional marker in effusion cytology.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Keratin-5 / metabolism. Keratin-6 / metabolism. Lung Neoplasms / metabolism. Mesothelioma / metabolism. Pleural Effusion / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Humans. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / metabolism. Pleural Effusion, Malignant / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18833821.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-5; 0 / Keratin-6
  •  go-up   go-down


53. Ikeda K, Tate G, Suzuki T, Kitamura T, Mitsuya T: IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology. Hum Pathol; 2010 May;41(5):745-50
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
  • Differentiating reactive mesothelial cells from metastatic carcinoma and malignant mesothelioma is critical in effusion cytology.
  • Numerous immunohistochemical/cytochemical reports use various antibodies in effusion samples, and most antibodies differentiate metastatic adenocarcinoma from malignant mesothelioma, but no antibodies help distinguish malignant mesothelioma from reactive mesothelial cells.
  • IMP3/L523S has been identified in several human malignant tumors.
  • A total of 229 cases of pleural and peritoneal effusion cytospecimens were evaluated for the study, including 39 benign effusions with reactive mesothelial cells and 190 metastatic malignant effusions.
  • IMP3 immunoreactivity was observed in 2 (5.1%) of 39 cases of reactive mesothelial cells, 138 (72.6%) of 190 cases of malignant effusion, 4 (36.4%) of 11 cases of malignant mesothelioma, 106 (75.7%) of 140 cases of metastatic adenocarcinoma, and 8 (100%) of 8 cases of squamous cell carcinoma.
  • In the peritoneal effusions, the sensitivity for the diagnosis of metastatic adenocarcinoma to distinguish reactive mesothelial cells was 92.3%.
  • However, the IMP3 antibody is a highly specific marker for malignant lesions, and thus, IMP3 staining is useful for distinguishing neoplastic cells from reactive mesothelial cells in effusion samples.
  • [MeSH-major] Adenocarcinoma / metabolism. Ascitic Fluid / metabolism. Biomarkers, Tumor / metabolism. Mesothelioma / metabolism. Neoplasm Proteins / metabolism. Pleural Effusion, Malignant / metabolism. RNA-Binding Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20060157.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins
  •  go-up   go-down


54. Garg K, Lee P, Ro JY, Qu Z, Troncoso P, Ayala AG: Adenomatoid tumor of the adrenal gland: a clinicopathologic study of 3 cases. Ann Diagn Pathol; 2005 Feb;9(1):11-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatoid tumor of the adrenal gland: a clinicopathologic study of 3 cases.
  • Adenomatoid tumors are relatively uncommon benign neoplasms of mesothelial origin, usually occurring in the male and female genital tracts.
  • Rare extragenital adenomatoid tumors have been identified in the adrenal glands, heart, mesentery, pleura, and lymph nodes.
  • In the adrenal gland, adenomatoid tumors may pose a diagnostic challenge.
  • Because of its glandular pattern, an adenomatoid tumor may be confused with an adenocarcinoma.
  • We present 3 cases of adrenal adenomatoid tumors, including one with a concurrent large hemorrhagic vascular adrenal cyst.
  • The adenomatoid tumors were unilateral, appeared solid and white, and varied from 1.7 to 4.2 cm in diameter.
  • One patient presented with abdominal pain due to the presence of a concurrent large adrenal cyst.
  • The tumor was an incidental radiological finding in another case and was discovered during the course of a workup for hypertension in the third case.
  • The light microscopic appearances were consistent with those of typical adenomatoid tumors.
  • Immunohistochemical stains for calretinin and cytokeratin 5/6 were positive, confirming the tumors' mesothelial origin.
  • In our experience, the key to the diagnosis of this rare benign tumor is to consider adenomatoid tumor in the differential diagnosis of any glandular tumor occurring in the adrenal gland.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Biomarkers, Tumor / metabolism. Calbindin 2. Carcinoma, Signet Ring Cell / diagnosis. Carcinoma, Signet Ring Cell / secondary. Cysts / complications. Cysts / metabolism. Cysts / pathology. Diagnosis, Differential. Humans. Immunohistochemistry. Keratins / metabolism. Male. Middle Aged. S100 Calcium Binding Protein G / metabolism. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15692945.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 68238-35-7 / Keratins
  •  go-up   go-down


55. El-Daly H, Rao P, Palazzo F, Gudi M: A rare entity of an unusual site: adenomatoid tumour of the adrenal gland: a case report and review of the literature. Patholog Res Int; 2010;2010:702472
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare entity of an unusual site: adenomatoid tumour of the adrenal gland: a case report and review of the literature.
  • This is a case report of a 51 year old male who was found to have an incidental left sided non-functioning adrenal mass on routine medical examination and which was confirmed by CT and MRI scans.
  • On gross examination the tumour was a solitary well circumscribed solid-cystic mass with a homogenous pinkish white cut surface.
  • On microscopic examination, the tumour was composed of variably sized tubules and fenestrated channels lined by bland cuboidal cells to epithelioid cells.
  • Immunohistochemically the tumour cells stained with calretinin, Cam5.2, CK7, vimentin and focally with EMA.
  • A diagnosis of an adenomatoid tumour as made.
  • Adenomatoid tumours are rare benign tumours of mesothelial derivation.
  • The adrenal gland is devoid of a mesothelial lining and the most accepted hypothesis for an adenomatoid tumour originating in the adrenal gland is derivation from mesothelial rests.
  • As the adrenal gland is an extremely rare site of occurrence for an adenomatoid tumour, it is frequently mistaken for adrenocortical tumours or a pheochromocytoma clinically and radiologically.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21151721.001).
  • [ISSN] 2042-003X
  • [Journal-full-title] Pathology research international
  • [ISO-abbreviation] Patholog Res Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2990199
  •  go-up   go-down


56. Hamamatsu A, Arai T, Iwamoto M, Kato T, Sawabe M: Adenomatoid tumor of the adrenal gland: case report with immunohistochemical study. Pathol Int; 2005 Oct;55(10):665-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatoid tumor of the adrenal gland: case report with immunohistochemical study.
  • Adrenal adenomatoid tumor (AT) is a recently recognized disease with marked male predominance.
  • Herein is presented a case of adrenal AT incidentally found in a 30-year-old man and results of immunohistochemical examination of the tumor.
  • Cut surface showed a relatively well-circumscribed firm tumor with a white solid appearance.
  • Histologically, the tumor had the typical appearance of AT described in the genital tract.
  • Immunohistochemically, the tumor cells were positive for calretinin, D2-40, WT1, mesothelial cell antigen, CA125, thrombomodulin, vimentin and cytokeratins (stained by AE1 + AE3, OV-TL 12/30, CAM5.2 and MNF116), and negative for endothelial markers (CD31, CD34 and factor VIII-related antigen) and CD56.
  • CD56-positive adrenocortical cells were diffusely scattered in the tumor, especially in its periphery.
  • These findings confirm mesothelial origin of the tumor and suggest that this tumor has little relation to sex hormone despite male predominance.
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Coronary Thrombosis / mortality. Coronary Thrombosis / pathology. Fatal Outcome. Humans. Immunoenzyme Techniques. Male

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16185299.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


57. Yasumitsu A, Tabata C, Tabata R, Hirayama N, Murakami A, Yamada S, Terada T, Iida S, Tamura K, Fukuoka K, Kuribayashi K, Nakano T: Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol; 2010 Apr;5(4):479-83
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
  • INTRODUCTION: Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin associated with asbestos exposure.
  • METHODS: Serum concentrations of VEGF were measured in 51 patients with MPM and 42 individuals with benign asbestos-related diseases (asbestosis or pleural plaques) or who were healthy despite asbestos exposure.
  • [MeSH-major] Asbestosis / blood. Biomarkers, Tumor / blood. Mesothelioma / blood. Pleural Neoplasms / blood. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Aged. Asbestos / adverse effects. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Neoplasm Staging. Occupational Exposure. Prognosis. ROC Curve. Survival Rate

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Oncol. 2011 May;6(5):971-2 [21623273.001]
  • (PMID = 20357617.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 1332-21-4 / Asbestos
  •  go-up   go-down


58. Miller DV, Tazelaar HD: Cardiovascular pseudoneoplasms. Arch Pathol Lab Med; 2010 Mar;134(3):362-8
MedlinePlus Health Information. consumer health - Heart Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Primary cardiac tumors are rare and the great majority are benign neoplasms.
  • OBJECTIVE: The general clinical, imaging, gross pathologic, and histologic features of 5 important pseudoneoplasms (inflammatory myofibroblastic tumor, hamartoma of mature cardiac myocytes, mesothelial/monocytic cardiac excrescences, calcified amorphous tumor, and lipomatous hypertrophy of the atrial septum) are discussed, with an emphasis on features differentiating them from other benign and malignant tumors.

  • MedlinePlus Health Information. consumer health - Heart Disease in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Pathol Lab Med. 2010 Nov;134(11):1584-6 [21043810.001]
  • (PMID = 20196664.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 37
  •  go-up   go-down


59. Johnston FM, Tan MC, Tan BR Jr, Porembka MR, Brunt EM, Linehan DC, Simon PO Jr, Plambeck-Suess S, Eberlein TJ, Hellstrom KE, Hellstrom I, Hawkins WG, Goedegebuure P: Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. Clin Cancer Res; 2009 Nov 1;15(21):6511-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Mesothelin is a glycoprotein expressed on normal mesothelial cells and is overexpressed in several histologic types of tumors including pancreatic adenocarcinomas.
  • A soluble form of mesothelin has been detected in patients with ovarian cancer and malignant mesothelioma, and has prognostic value.
  • We conducted a study on the potential clinical utility of mesothelin as a biomarker for pancreatic disease and therapeutic target pancreatic cancer.
  • EXPERIMENTAL DESIGN: Tumor cell-bound and soluble mesothelin in patients was evaluated by immunohistochemistry and ELISA, respectively.
  • RESULTS: All tumor tissue from patients with pancreatic adenocarcinoma expressed mesothelin (n = 10).
  • Circulating mesothelin protein was detected in patients with pancreatic adenocarcinoma (73 of 74 patients) and benign pancreatic disease (5 of 5) but not in healthy individuals.
  • CONCLUSIONS: Circulating mesothelin is a useful biomarker for pancreatic disease.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2000 Apr;20(8):2902-6 [10733593.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1520-6 [18559570.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3862-8 [11751476.001]
  • [Cites] J Immunol. 2002 Sep 1;169(5):2756-61 [12193750.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1418-28 [14576474.001]
  • [Cites] Lancet. 2003 Nov 15;362(9396):1612-6 [14630441.001]
  • [Cites] Pancreas. 2004 Jan;28(1):e26-31 [14707745.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):9190-8 [14676194.001]
  • [Cites] J Exp Med. 2004 Aug 2;200(3):297-306 [15289501.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):9-15 [15385104.001]
  • [Cites] Int J Cancer. 1992 Feb 1;50(3):373-81 [1735605.001]
  • [Cites] J Biol Chem. 1994 Jan 14;269(2):805-8 [8288629.001]
  • [Cites] J Biol Chem. 1995 Sep 15;270(37):21984-90 [7665620.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40 [8552591.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11531-6 [10500211.001]
  • [Cites] Gene Ther. 2005 Jan;12(2):187-93 [15526007.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3814-20 [15897581.001]
  • [Cites] Nat Rev Cancer. 2005 Jun;5(6):459-67 [15905855.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S109-11 [15950789.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6342-51 [16144939.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):10079-87 [16267034.001]
  • [Cites] Am J Clin Pathol. 2005 Dec;124(6):838-45 [16416732.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):447-53 [16428485.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):827-31 [16467095.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1365-72 [16489095.001]
  • [Cites] Int J Oncol. 2006 Jun;28(6):1419-28 [16685444.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1014-20 [16702385.001]
  • [Cites] Mol Cancer. 2006;5(1):50 [17067392.001]
  • [Cites] Vaccine. 2007 Jan 2;25(1):127-35 [16930783.001]
  • [Cites] Clin Chem. 2007 Apr;53(4):666-72 [17289801.001]
  • [Cites] Gene Ther. 2007 Jun;14(12):921-9 [17377599.001]
  • [Cites] Gene Ther. 2007 Aug;14(16):1189-98 [17581599.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5076-81 [17785560.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5144-9 [17785569.001]
  • [Cites] Chest. 2007 Oct;132(4):1239-46 [17646232.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):7166-71 [18056197.001]
  • [Cites] Cancer Immun. 2007;7:20 [18088084.001]
  • [Cites] Mol Cancer Ther. 2008 Feb;7(2):286-96 [18281514.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1455-63 [18316569.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):145-56 [11134207.001]
  • (PMID = 19843662.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA134487; United States / NCI NIH HHS / CA / T32 CA009621; United States / NCI NIH HHS / CA / T32 CA009621-20; United States / NCI NIH HHS / CA / P30 CA091842; United States / NIDDK NIH HHS / DK / 5P30 DK052574; United States / NCI NIH HHS / CA / CA009621-20; United States / NIDDK NIH HHS / DK / P30 DK052574; United States / NCI NIH HHS / CA / R01 CA134487-01; United States / NCI NIH HHS / CA / T32CA009621
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  • [Other-IDs] NLM/ NIHMS135383; NLM/ PMC2782601
  •  go-up   go-down


60. Passman C, Urban D, Klemm K, Lockhart M, Kenney P, Kolettis P: Testicular lesions other than germ cell tumours: feasibility of testis-sparing surgery. BJU Int; 2009 Feb;103(4):488-91
MedlinePlus Health Information. consumer health - Testicular Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular lesions other than germ cell tumours: feasibility of testis-sparing surgery.
  • Patients with atrophy, germ cell tumours, infection or torsion were excluded.
  • The study comprised men who had radical orchidectomy for suspected germ-cell tumour but had other final pathology, and those where testis-sparing surgery was attempted for a presumed benign lesion.
  • The lesions could be categorized as inflammatory (three hyalinized fibrosis, two sarcoidosis, one chronic inflammation), cystic (one epidermoid cyst, one unilocular cyst), benign neoplasms (two adenomatoid tumours, one Leydig cell tumour, one capillary haemangioma) or malignant neoplasms (one lymphoma).
  • In the other five, testis-sparing surgery was not attempted because the preoperative impression was that of a germ cell tumour.
  • CONCLUSION: Testis-sparing surgery might be possible if there is significant suspicion of a benign lesion.
  • [MeSH-minor] Adolescent. Adult. Aged. Feasibility Studies. Humans. Leydig Cell Tumor / pathology. Leydig Cell Tumor / surgery. Leydig Cell Tumor / ultrasonography. Male. Middle Aged. Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Germ Cell and Embryonal / surgery. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18793303.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


61. Lyons-Boudreaux V, Mody DR, Zhai J, Coffey D: Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology? Arch Pathol Lab Med; 2008 Jan;132(1):23-8
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Differentiating reactive effusion, malignant mesothelioma, and metastatic adenocarcinoma in body cavity fluids can be challenging.
  • OBJECTIVE: To evaluate the efficacy of 5 immunohistochemical markers in the differential diagnosis of reactive mesothelial proliferation, malignant mesothelioma, and metastatic adenocarcinoma in body cavity fluids.
  • DESIGN: A total of 72 formalin-fixed, paraffin-embedded cell block specimens from pleural and peritoneal effusions, including 5 mesotheliomas, 48 adenocarcinomas, and 19 benign effusions were stained with antibodies against calretinin, D2-40, XIAP, MOC-31, and WT1.
  • RESULTS: All benign effusions and mesotheliomas demonstrated diffuse membranous staining with D2-40.
  • All mesotheliomas displayed calretinin positivity, whereas only 58% of benign effusions stained focally with calretinin.
  • MOC-31 was positive in all cases of adenocarcinoma, whereas all benign effusions and mesotheliomas were negative.
  • However, background reactive mesothelial cells were positive for calretinin and D2-40.
  • Overall, D2-40 highlighted more mesothelial cells than calretinin.
  • WT1 was positive in 50% of benign effusions, 60% of mesotheliomas, and 27% of adenocarcinomas.
  • XIAP stained most mesotheliomas (80%), some adenocarcinomas (51%), and rare benign effusions (11%).
  • CONCLUSIONS: MOC-31 and D2-40 were very sensitive and specific markers of epithelial and mesothelial cells, respectively.
  • Compared with calretinin, D2-40 was a more sensitive marker of mesothelial cells.
  • [MeSH-major] Adenocarcinoma. Biomarkers, Tumor / analysis. Body Fluids / chemistry. Epithelium / chemistry. Mesothelioma / chemistry. Pleural Effusion, Malignant / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18181669.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 0 / WT1 Proteins; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human; 0 / monoclonal antibody D2-40
  •  go-up   go-down


62. Jain M, Agarwal S, Mandal S: Variation in clinical and genitourinary lesions associated with pulmonary hypoplasia in Potter's syndrome--two autopsy reports. Indian J Pathol Microbiol; 2006 Jul;49(3):416-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present two autopsy cases which presented with abnormal facies, oligohydramnios, pulmonary hypoplasia and genitourinary abnormality.
  • One case presented with infantile polycystic kidney whereas in the other case both the kidneys were normal but had adenomatoid tumour of left testis.
  • In both the cases pulmonary hypoplasia was the cause of death rather than genitourinary abnormality.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001905.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


63. Ordóñez NG: Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas. Hum Pathol; 2005 Nov;36(11):1163-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas.
  • The differential diagnosis between peritoneal mesotheliomas and serous carcinomas involving the peritoneum may be difficult, but it can be facilitated by the use of immunohistochemistry.
  • To determine whether estrogen receptors (ER) or progesterone receptors (PR) may have any value as immunohistochemical markers for discriminating between these malignancies, 40 serous carcinomas of the ovary metastatic to the peritoneum, 7 primary peritoneal serous carcinomas, 30 epithelioid peritoneal malignant mesotheliomas, 5 well-differentiated papillary mesotheliomas, and 4 adenomatoid tumors were immunostained for ER and PR.
  • None of the mesotheliomas or adenomatoid tumors expressed ER or PR.
  • It is concluded that, because of its high sensitivity for serous carcinomas, ER immunostaining could be very useful in distinguishing between serous carcinomas and peritoneal mesotheliomas.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cystadenocarcinoma, Serous / diagnosis. Mesothelioma / diagnosis. Peritoneal Neoplasms / diagnosis. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2005 Nov;36(11):1153 [16260266.001]
  • (PMID = 16260268.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


64. Hong R, Choi DY, Choi SJ, Lim SC: Multicentric infarcted leiomyoadenomatoid tumor: a case report. Int J Clin Exp Pathol; 2009;2(1):99-103

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric infarcted leiomyoadenomatoid tumor: a case report.
  • Adenomatoid tumor is a benign, usually small lesion that may be found within the wall of fallopian tubes or beneath the uterine serosa near the uterine cornu.
  • It is often accompanied by smooth muscle hypertrophy that may obscure the adenomatoid tumor.
  • We herein report a very unusual case of infarcted leiomyoadenomatoid tumor of the uterus and ovary in a 24-year-old woman who presented with severe lower abdominal pain and masses in the uterus and right ovary.
  • Laparoscopy-assisted transvaginal mass removal was performed under the clinical impression of a uterine leiomyoma and benign ovarian teratoma.
  • On a microscopic examination, prominent fascicles of smooth muscle separated or infiltrated by cuboidal or signet ring-like vacuolated cells, as well as tubular formations lined by flattened mesothelial cells and extensive necrosis were observed in both masses.
  • The microscopic appearance often suggested the possibility of a malignant neoplasm due to irregular pseudoinfiltration with atypical cuboidal cells and the paucity of a typical adenomatoid tumor due to infarction, and the presence of epithelial-appearing cells in the hypertrophic smooth muscle bundles that mimicked an infiltrating carcinoma for a leiomyoma or myometrium.
  • These unemphasized features of leiomyoadenomatoid tumors may potentially lead to more aggressive therapy than warranted if not correctly interpreted, especially for infarcted cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Pathol. 2007 Jan;26(1):16-20 [17197891.001]
  • [Cites] Arch Gynecol Obstet. 2001 Aug;265(3):151-4 [11561745.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):34-40 [11781521.001]
  • [Cites] Am J Surg Pathol. 2004 Jan;28(1):77-83 [14707867.001]
  • [Cites] Histopathology. 1992 Jan;20(1):57-61 [1371104.001]
  • [Cites] Histopathology. 1980 Jul;4(4):437-43 [7429432.001]
  • [Cites] Am J Clin Pathol. 1981 Nov;76(5):627-35 [7293978.001]
  • [Cites] Int J Gynecol Pathol. 1991;10(3):296-301 [1917277.001]
  • [Cites] Int J Gynecol Pathol. 1991;10(4):364-71 [1774107.001]
  • [Cites] Ann Diagn Pathol. 2003 Oct;7(5):273-7 [14571427.001]
  • (PMID = 18830386.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Leiomyoadenomatoid tumor / infarction / ovary / uterus
  •  go-up   go-down


65. Robinson LA: Solitary fibrous tumor of the pleura. Cancer Control; 2006 Oct;13(4):264-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the pleura.
  • BACKGROUND: The solitary fibrous tumor of the pleura (SFTP) is a rare primary tumor arising from mesenchymal cells in the areolar tissue subjacent to the mesothelial-lined pleura.
  • The tumor appears to be unrelated to malignant pleural mesothelioma, the most common primary tumor of the pleura.
  • METHODS: In just over half of these cases, the neoplasm presents as an asymptomatic mass, is often quite large, and is benign in 78% to 88% of patients.
  • The initial evaluation and diagnosis, tumor classification, surgical treatment, results of therapy, and long-term prognosis are reviewed, based on a selective review of the literature from MEDLINE beginning 1980.
  • RESULTS: Complete en bloc surgical resection is the preferred treatment of benign and malignant varieties of the tumor.
  • The pedunculated tumors attached to the visceral pleura can be effectively treated with a wedge resection of lung.
  • Sessile tumors arising on the lung require a larger lung resection.
  • Sessile tumors on the chest wall require wide local excision, often with chest wall resection because of their propensity for local recurrence.
  • CONCLUSIONS: Benign SFTP has a high cure rate and an 8% local recurrence rate that is usually amenable to curative re-excision.
  • The majority of patients with recurrent disease die of the tumor within 2 years.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17075563.001).
  • [ISSN] 1073-2748
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


66. Vacharadze K, Burkadze G, Turashvili G, Kiria N: Argyrophilic nucleolar organizer regions in benign and malignant mesothelial lesions. Georgian Med News; 2005 Nov;(128):91-3
MedlinePlus Health Information. consumer health - Lung Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Argyrophilic nucleolar organizer regions in benign and malignant mesothelial lesions.
  • The aim our study was to assess the usefulness of AgNOR stain in distinguishing between benign and malignant mesothelial lesions.
  • The patients were divided into three groups: group I -- reactive mesothelium (71 cases), group II -- hyperplastic mesothelium (66 cases), group III -- epithelial type mesothelioma (52 cases).
  • Our results show that AgNOR staining is useful to differentiate epithelial type mesothelioma and benign mesothelial lesions such as reactive and hyperplastic mesothelium.
  • AgNOR is highly sensitive, specific and cost-effective technology which can be used as an ancillary diagnostic approach for distinguishing between reactive and/or hyperplastic changes of mesothelium as well as in differential diagnosis of epithelial type mesothelioma.
  • [MeSH-major] Antigens, Nuclear / metabolism. Lung Diseases / metabolism. Lung Diseases / pathology. Neoplasms, Mesothelial / metabolism. Neoplasms, Mesothelial / pathology. Nuclear Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16369075.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Nuclear Proteins; 0 / nucleolar organizer region associated proteins
  •  go-up   go-down


67. Pacheco AJ, Torres JL, de la Guardia FV, Arrabal Polo MA, Gómez AZ: Intraparenchymatous adenomatoid tumor dependent on the rete testis: A case report and review of literature. Indian J Urol; 2009 Jan;25(1):126-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraparenchymatous adenomatoid tumor dependent on the rete testis: A case report and review of literature.
  • The adenomatoid tumor is the most frequent paratesticular tumor.
  • It is a benign tumor, which in women is mainly found in the uterus and the fallopian tubes, while in men it is most frequently found in the epididymis.
  • The clinical signs and imaging studies are, on many occasions, difficult to differentiate from malign intratesticular solid tumor, which can result in unnecessary orchidectomies.
  • We present a new case of intraparenchymatous adenomatoid tumor dependent on the rete testis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 1996;30(1):127-8 [8854081.001]
  • [Cites] J Urol. 2004 May;171(5):1765-72 [15076274.001]
  • [Cites] Urology. 1992 Oct;40(4):359-61 [1413358.001]
  • [Cites] J Clin Ultrasound. 1992 Sep;20(7):479-80 [1324954.001]
  • (PMID = 19468443.001).
  • [ISSN] 0970-1591
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2684313
  • [Keywords] NOTNLM ; Adenomatoid tumor / diagnosis and ultrasound
  •  go-up   go-down


68. Füredi G, Szilágyi A, Bencsik Z, Altorjay A: [Adenomatoid tumor of the adrenal gland. Case report and review of the literature]. Orv Hetil; 2007 Aug 19;148(33):1563-5
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumor of the adrenal gland. Case report and review of the literature].
  • [Transliterated title] A mellékvese adenomatoid tumora, avagy irodalmi barangolás egy igen ritka mesothelialis daganat nyomán.
  • Adenomatoid tumors of the adrenal gland are rather rare, asymptomatic neoplasias with benign behavior and usually are diagnosed incidentally.
  • The authors report a case of an adenomatoid tumor of the right adrenal gland in a 32-year-old man who sought evaluation because of fever and renal pain.
  • During investigation a tumor, localized in right adrenal gland, was identified by ultrasonography and CT.
  • The patient underwent adrenalectomy with histopathological and immunohistochemical diagnosis of adenomatoid tumor of the adrenal gland.
  • Based on literature data the epidemiology, symptoms, differential diagnosis, treatments, histopathology and prognosis of adenomatoid tumors of the adrenal gland are discussed.
  • [MeSH-major] Adenomatoid Tumor. Adrenal Gland Neoplasms
  • [MeSH-minor] Adrenalectomy. Adult. Biomarkers, Tumor / analysis. Diagnosis, Differential. Fever / etiology. Humans. Immunohistochemistry. Male. Pain / etiology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17686675.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 11
  •  go-up   go-down


69. Sieunarine K, Cowie AS, Bartlett JD, Lindsay I, Smith JR: A novel approach in the management of a recurrent adenomatoid tumor of the uterus utilizing a Strassman technique. Int J Gynecol Cancer; 2005 Jul-Aug;15(4):671-5
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel approach in the management of a recurrent adenomatoid tumor of the uterus utilizing a Strassman technique.
  • Adenomatoid tumors of the uterus are uncommon benign lesions derived from mesothelium, with a prevalence of 1.2% in one study of 1 000 unselected hysterectomy specimens.
  • They are usually small and near the serosal surface; however, they may be large and diffuse (giant adenomatoid tumors).
  • This transpired to be an adenomatoid tumor, and she underwent three transcervical resections of the tumor (TCRT) over a period of 12 months for tumor recurrence and failure of symptom resolution.
  • A specialist opinion on the suitability of vascular embolization of the tumor judged that it would be ineffective for this lesion.
  • She then underwent a Strassman procedure and removal of the adenomatoid tumor.
  • This involved dissection of ureters and pelvic vasculature, selective temporary ligation of uterine arteries, hemisection of the uterus, and excision of the tumor with frozen sections to ensure clear tumor margins and resuturing of the uterine halves.
  • Temporary vascular occlusion of the uterine arteries and ovarian vessels allowed a Strassman procedure, which resulted in successful resection of a recurrent giant adenomatoid tumor of the uterus, with fertility preservation in a young nulliparous woman.
  • Two and a half years on there is no evidence of tumor recurrence.
  • [MeSH-major] Adenomatoid Tumor / surgery. Gynecologic Surgical Procedures / methods. Neoplasm Recurrence, Local / surgery. Uterine Neoplasms / surgery. Uterus / blood supply

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16014122.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Timonera ER, Paiva ME, Lopes JM, Eloy C, van der Kwast T, Asa SL: Composite adenomatoid tumor and myelolipoma of adrenal gland: report of 2 cases. Arch Pathol Lab Med; 2008 Feb;132(2):265-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite adenomatoid tumor and myelolipoma of adrenal gland: report of 2 cases.
  • Adenomatoid tumor and myelolipoma are benign, hormonally inactive tumors that are often incidental findings in the adrenal glands.
  • Myelolipoma is more common than adenomatoid tumor in this location but both are rare, and as yet, the pathogenesis of both remains unclear.
  • We report 2 cases of composite adenomatoid tumor and myelolipoma, incidentally found in the adrenal gland on investigation for other diseases.
  • To our knowledge, composite adenomatoid tumor and myelolipoma of adrenal gland has not been previously reported.

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18251587.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Sangoi AR, McKenney JK, Schwartz EJ, Rouse RV, Longacre TA: Adenomatoid tumors of the female and male genital tracts: a clinicopathological and immunohistochemical study of 44 cases. Mod Pathol; 2009 Sep;22(9):1228-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatoid tumors of the female and male genital tracts: a clinicopathological and immunohistochemical study of 44 cases.
  • Adenomatoid tumors of the female and male genital tracts are well characterized as mesothelial in origin, but a detailed histological and immunohistochemical analysis comparing both traditional and newer mesothelial markers across gender and site has not been formally conducted.
  • A variety of morphologic features previously described as characteristic of adenomatoid tumors were evaluated in 44 adenomatoid tumors from the male and female genital tracts.
  • All (n=44) the adenomatoid tumors from both the female and male genital tracts demonstrated a distinctive thread-like bridging strand pattern.
  • Lymphoid aggregates were seen in all 12 adenomatoid tumors of male patients, but in only 4 of 32 (13%) tumors in female patients (P<0.0001).
  • The remaining morphologic features were variably present with no clear sex predilection.
  • Pankeratin, calretinin, and D2-40 reactivity were identified in all female (n=32) and male (n=12) genital tract adenomatoid tumors.
  • Adenomatoid tumors expressed WT-1 in 11/12 (92%) male patients and in 31/32 (97%) female patients.
  • In male patients, reactivity for CK5/6 and caldesmon was found in 1/12 (8%) and 0/12 (0%) adenomatoid tumors (respectively), whereas reactivity in female patients was found in 5/32 (16%) and 1/32 (3%); respectively.
  • Female tumors differ from their male counterparts by the frequent absence of lymphoid aggregates and the presence of a circumscribed margin when occurring in the fallopian tube.
  • Of the putative mesothelial markers evaluated, calretinin, D2-40, and WT-1 show a similar immunoprofile and have a higher sensitivity than CK5/6 and caldesmon in genital tract adenomatoid tumors.
  • [MeSH-major] Adenomatoid Tumor / pathology. Biomarkers, Tumor / analysis. Genital Neoplasms, Female / pathology. Genital Neoplasms, Male / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19543245.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


72. Boldú J, Eguía VM: [Benign pleural diseases induced by asbestos]. An Sist Sanit Navar; 2005;28 Suppl 1:21-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign pleural diseases induced by asbestos].
  • Together with the prolonged latency existing between exposure and the disease, this means that for many years we will continue to see pleural clinical manifestations from past exposure, in spite of the increasingly limited use of asbestos in recent decades.
  • This exposure can show itself in different manifestations, both malign, such as mesothelioma, and benign, principally benign pleural effusion, pleural plaques, diffuse pleural fibrosis and massive atelectasis.

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Collapsed Lung.
  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15915168.001).
  • [ISSN] 1137-6627
  • [Journal-full-title] Anales del sistema sanitario de Navarra
  • [ISO-abbreviation] An Sist Sanit Navar
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


73. Addis B, Roche H: Problems in mesothelioma diagnosis. Histopathology; 2009 Jan;54(1):55-68
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Problems in mesothelioma diagnosis.
  • Many centres are now seeing increasing numbers of patients with malignant mesothelioma.
  • This presents pathologists involved in making the diagnosis with a number of problems, which can be divided into those encountered in making the distinction between mesothelioma and benign changes and those experienced in separating mesotheliomas from other types of epithelial and connective tissue tumours.
  • Immunohistochemistry plays a major role in helping to make the diagnosis, but it should be interpreted with due regard to the clinical setting and radiological features, and with a knowledge of the wide morphological variations seen in mesothelioma.
  • It includes a discussion of some of the less common variants of mesothelioma and other pleural-based tumours that enter into the differential diagnosis.
  • [MeSH-major] Mesothelioma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19054156.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 101
  •  go-up   go-down


74. Shiau CS, Chang MY, Hsieh CC, Hsieh TT, Chiang CH: Meigs' syndrome in a young woman with a normal serum CA-125 level. Chang Gung Med J; 2005 Aug;28(8):587-91
Genetic Alliance. consumer health - Young syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report on a 27-year-old woman who presented with an ovarian solid tumor (20 x 15 cm) and massive ascites.
  • Cytologic study of the pleural effusion showed reactive mesothelial cells without evidence of malignancy.
  • Postoperatively, the pleural effusion spontaneously resolved, and the microscopic examination revealed a benign fibroma-thecoma, confirming the diagnosis of Meigs' syndrome.
  • The symptoms resolved after removal of this pelvic tumor.
  • This is an unusual case of a young female with Meigs' syndrome and a normal serum CA-125 level.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16265850.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


75. Pauser U, Kosmahl M, Sipos B, Klöppel G: [Mesenchymal tumors of the pancreas. Surprising, but not uncommon]. Pathologe; 2005 Feb;26(1):52-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mesenchymal tumors of the pancreas. Surprising, but not uncommon].
  • Mesenchymal tumors of the pancreas are rare.
  • They are resected because a solid or cystic pancreatic tumor is suspected.
  • Benign mesenchymal tumors comprise lymphangiomas, hemangiomas, schwannomas, solitary fibrous tumors, adenomatoid tumors, clear cell tumors, and hamartomas.
  • Malignant mesenchymal tumors include leiomyosarcomas, malignant peripheral nerve sheath tumors (MPNST), liposarcomas, malignant fibrous histiocytomas, Ewing's sarcomas, and primitive neuroectodermal tumors (PNET).
  • It is important to differentiate these tumors from anaplastic carcinomas and retroperitoneal tumors that infiltrate pancreatic tissue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol Hepatol. 2004 Apr;19(4):467-70 [15012791.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(5):419-22 [8322457.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):613-7 [12808068.001]
  • [Cites] Am J Surg Pathol. 1981 Sep;5(6):597-602 [7325276.001]
  • [Cites] Virchows Arch. 2002 Feb;440(2):128-33 [11964041.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2150-8 [9610694.001]
  • [Cites] Acta Pathol Jpn. 1985 Jul;35(4):975-9 [4072679.001]
  • [Cites] Br Med J. 1977 Mar 26;1(6064):814 [851741.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1720-3 [7370927.001]
  • [Cites] Pancreas. 2003 Jul;27(1):14-9 [12826900.001]
  • [Cites] Histopathology. 2001 Feb;38(2):105-10 [11207823.001]
  • [Cites] Histopathology. 1998 Nov;33(5):485-7 [9839177.001]
  • [Cites] Virchows Arch. 1999 Jul;435(1):37-42 [10431844.001]
  • [Cites] Hum Pathol. 1992 Nov;23(11):1309-12 [1427759.001]
  • [Cites] Ann Diagn Pathol. 2001 Jun;5(3):129-40 [11436166.001]
  • [Cites] Histopathology. 1993 Nov;23(5):475-7 [8314223.001]
  • [Cites] J Thorac Cardiovasc Surg. 1970 Sep;60(3):392-401 [5451736.001]
  • [Cites] Pediatr Radiol. 1983;13(5):287-9 [6622090.001]
  • [Cites] Mod Pathol. 1994 Feb;7(2):200-4 [7911997.001]
  • [Cites] J Radiol. 2001 Dec;82(12 Pt 1):1723-5 [11917638.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):1040-7 [12170091.001]
  • [Cites] Cancer. 1989 Dec 1;64(11):2303-8 [2553244.001]
  • [Cites] Ultrastruct Pathol. 1998 May-Jun;22(3):227-31 [9793202.001]
  • [Cites] Arch Pathol Lab Med. 2003 Nov;127(11):1513-6 [14567749.001]
  • [Cites] Pathologe. 1997 May;18(3):233-7 [9273541.001]
  • [Cites] Hum Pathol. 1989 Dec;20(12):1215-7 [2556342.001]
  • [Cites] J Pediatr Surg. 1976 Oct;11(5):827-30 [993954.001]
  • [Cites] Acta Pathol Jpn. 1987 Mar;37(3):503-10 [3618222.001]
  • [Cites] Mod Pathol. 1998 Dec;11(12):1178-82 [9872648.001]
  • [Cites] Pathologe. 2002 Mar;23 (2):161-6 [12001534.001]
  • [Cites] Am J Surg Pathol. 1998 Apr;22(4):412-8 [9537467.001]
  • [Cites] Am J Clin Oncol. 2001 Apr;24(2):198-200 [11319298.001]
  • [Cites] Am J Gastroenterol. 1994 Aug;89(8):1261-2 [8053450.001]
  • (PMID = 15592845.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


76. Inamoto T, Yamada T, Ohnuma K, Kina S, Takahashi N, Yamochi T, Inamoto S, Katsuoka Y, Hosono O, Tanaka H, Dang NH, Morimoto C: Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors. Clin Cancer Res; 2007 Jul 15;13(14):4191-200
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors.
  • PURPOSE: CD26 is a 110-kDa cell surface antigen with a role in tumor development.
  • In this report, we show that CD26 is highly expressed on the cell surface of malignant mesothelioma and that a newly developed humanized anti-CD26 monoclonal antibody (mAb) has an inhibitory effect on malignant mesothelioma cells in both in vitro and in vivo experiments.
  • EXPERIMENTAL DESIGN: Using immunohistochemistry, 12 patients' surgical specimens consisting of seven malignant mesothelioma, three reactive mesothelial cells, and two adenomatoid tumors were evaluated for expression of CD26.
  • The effects of CD26 on malignant mesothelioma cells were assessed in the presence of transfection of CD26-expressing plasmid, humanized anti-CD26 mAb, or small interfering RNA against CD26.
  • The in vivo growth inhibitory effect of humanized anti-CD26 mAb was assessed in human malignant mesothelioma cell mouse xenograft models.
  • RESULTS: In surgical specimens, CD26 is highly expressed in malignant mesothelioma but not in benign mesothelial tissues.
  • Moreover, our in vitro data indicate that humanized anti-CD26 mAb induces cell lysis of malignant mesothelioma cells via antibody-dependent cell-mediated cytotoxicity in addition to its direct anti-tumor effect via p27(kip1) accumulation.
  • In vivo experiments with mouse xenograft models involving human malignant mesothelioma cells show that humanized anti-CD26 mAb treatment drastically inhibits tumor growth in tumor-bearing mice, resulting in enhanced survival.
  • CONCLUSIONS: Our data strongly suggest that humanized anti-CD26 mAb treatment may have potential clinical use as a novel cancer therapeutic agent in CD26-positive malignant mesothelioma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Dipeptidyl Peptidase 4 / immunology. Lung Neoplasms / immunology. Mesothelioma / immunology
  • [MeSH-minor] Antigens, CD / genetics. Antigens, CD / immunology. Humans. Immunity, Cellular. Immunohistochemistry. Immunotherapy. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17634548.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; EC 3.4.14.5 / Dipeptidyl Peptidase 4
  •  go-up   go-down


77. Nagata S, Aishima S, Fukuzawa K, Takagi H, Yonemasu H, Iwashita Y, Kinoshita T, Wakasugi K: Adenomatoid tumour of the liver. J Clin Pathol; 2008 Jun;61(6):777-80
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatoid tumour of the liver.
  • An unusual primary adenomatoid tumour arising in the normal liver is described.
  • Hepatectomy was performed, and the patient is alive and free of disease 1 year postsurgery.
  • Grossly, the tumour showed a haemorrhagic cut surface with numerous microcystic structures.
  • Immunohistochemical studies showed that the epithelioid cells were strongly positive for a broad spectrum of cytokeratins (AE1/AE3, CAM5.2, epithelial membrane antigen and cytokeratin 7) and mesothelial markers (calretinin, Wilms' tumour 1 and D2-40).
  • Atypically, abundant capillaries were observed; however, the cystic proliferation of epithelioid cells with vacuoles and immunohistochemical profile of the epithelioid element were consistent with hepatic adenomatoid tumour.
  • [MeSH-major] Adenomatoid Tumor / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Calbindin 2. Hepatectomy. Humans. Immunohistochemistry. Keratins / analysis. Male. Neovascularization, Pathologic. S100 Calcium Binding Protein G / analysis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2003 Jun;16(6):613-7 [12808068.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):969-77 [12826889.001]
  • [Cites] Urology. 1975 Nov;6(5):635-41 [1189154.001]
  • [Cites] J Pathol. 1986 Apr;148(4):327-35 [3517266.001]
  • [Cites] J Clin Pathol. 2007 Jun;60(6):722-4 [17483249.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):562-82 [10091730.001]
  • [Cites] J Clin Ultrasound. 2005 Jun;33(5):233-6 [16047378.001]
  • [Cites] Scand J Gastroenterol Suppl. 2006;(243):102-15 [16782629.001]
  • [Cites] Curr Probl Diagn Radiol. 2007 May-Jun;36(3):107-23 [17484954.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1219-23 [8827028.001]
  • (PMID = 18505892.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ PMC2569191
  •  go-up   go-down


78. Shima M, Takahashi S, Maeda T, Masumori N, Itoh N, Tsukamoto T: [Adenomatoid tumor of the testis with testicular pain: a case report]. Hinyokika Kiyo; 2009 May;55(5):285-6
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumor of the testis with testicular pain: a case report].
  • The intraoperative findings showed a small, white, elastic solid, a smooth surface tumor that originated from the tunica albuginea of the right testis.
  • It seemed to be benign macroscopically and partial orchiectomy was performed.
  • Pathohistological examination revealed an adenomatoid tumor of the testis which originated from the rete testis.
  • Adenomatoid tumor of the testis is a rare benign tumor.
  • Therefore, we should be aware that an adenomatoid tumor of the testis can be one of the differential diagnoses of acute scrotum.
  • [MeSH-major] Adenomatoid Tumor / complications. Adenomatoid Tumor / surgery. Pain / etiology. Scrotum. Testicular Neoplasms / complications. Testicular Neoplasms / surgery
  • [MeSH-minor] Acute Disease. Adult. Diagnosis, Differential. Humans. Male. Orchiectomy

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19507549.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


79. Mitsui Y, Ueda Y, Suzuki T, Shincho M, Higuchi Y, Qiu J, Maruyama T, Kondoh N, Nojima M, Yamamoto S, Hirota S, Shima H: [A case of adenomatoid tumor of the testis treated by testis-sparing surgery: a case report]. Hinyokika Kiyo; 2008 May;54(5):383-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of adenomatoid tumor of the testis treated by testis-sparing surgery: a case report].
  • A 44-year-old man was referred to our hospital with a chief complaint of a painless left intrascrotal mass, palpable at the lower portion of the left testis.
  • Serum levels of tumor markers, human choriogenic gonadotropin (hCG), hCG-beta, and alpha fetoprotein were within the normal limits.
  • Ultrasonography revealed a hyperechoic mass 13 mm in diameter, which was demonstrated as a hypovascular tumor by Gadrinium-enhanced magnetic resonance imaging.
  • Since the tumor was diagnosed as a benign tumor by frozen section examination intraoperatively, testis-sparing surgery was performed.
  • Histological examination revealed adenomatoid tumor originating from the tunica alubuginea of testis.
  • Adenomatoid tumor of the testis is a rare benign tumor, and the present case is the 36th one in the Japanese literature.
  • [MeSH-major] Adenomatoid Tumor / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18546867.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 16
  •  go-up   go-down


80. Manjunath GV, Nandini NM, Sunila: Fine needle aspiration cytology of adenomatoid tumour--a case report with review of literature. Indian J Pathol Microbiol; 2005 Oct;48(4):503-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of adenomatoid tumour--a case report with review of literature.
  • Adenomatoid tumours are neoplasms of male and female genital tract with the epididymis being the most common site.
  • These benign tumours are asymptomatic or cause mild symptoms and a palpable mass.
  • Fine needle aspiration of these tumours is very useful to differentiate malignant from benign lesions and helps to avoid unnecessary aggressive surgical procedures.
  • FNAC of these benign epididymal tumours is diagnostic, rapid, reliable, conclusive and cost effective.
  • We are reporting a case of adenomatoid tumour of epididymis in a 41 year old male patient, diagnosed by FNAC and confirmed by histopathology.
  • [MeSH-major] Adenomatoid Tumor / pathology. Epididymis. Genital Neoplasms, Male / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366111.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 7
  •  go-up   go-down


81. Cabay RJ, Siddiqui NH, Alam S: Paratesticular papillary mesothelioma: a case with borderline features. Arch Pathol Lab Med; 2006 Jan;130(1):90-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paratesticular papillary mesothelioma: a case with borderline features.
  • Most often, mesotheliomas involve the serosal (serous) membranes of the pleura and peritoneum.
  • Sometimes, mesothelial proliferations are identified in other locations.
  • On very rare occasions, a mesothelioma is found within the tunica vaginalis of the paratesticular region.
  • We report a case of papillary mesothelioma of the tunica vaginalis in a 52-year-old man.
  • Although this lesion had papillary structures lined by a single layer of mesothelial cells with predominantly bland nuclear and cytologic features, there was evidence of a minimal presence of mesothelial cells in the underlying stroma.
  • This combination of benign and semimalignant characteristics can make the diagnosis of such a lesion problematic.
  • We think that a diagnosis of "borderline papillary mesothelioma" can be considered for similar mesothelial proliferations to allow for a possible increase in diagnostic accuracy and provide an enhanced informational platform from which patients and clinicians can benefit.
  • [MeSH-major] Mesothelioma / pathology. Peritoneal Neoplasms / pathology. Testicular Neoplasms / pathology. Testis / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Disease-Free Survival. Humans. Immunohistochemistry. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16390245.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


82. Carmignani L, Morabito A, Gadda F, Bozzini G, Rocco F, Colpi GM: Prognostic parameters in adult impalpable ultrasonographic lesions of the testicle. J Urol; 2005 Sep;174(3):1035-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: We performed a bibliographic search on PubMed, MEDLINE, EMBASE online databases from 1990 to May 2004 using search words such as sonographic lesions of the testicle, impalpable tumors of the testicle and impalpable testicular lesions.
  • Six articles were found that presented a description of the histological characteristics, patient age, lesion dimensions, presence of cryptorchidism and association with tumors in other parts of the body.
  • Histologically 15 of the lesions were Leydig cell tumors (31%), 12 (25%) seminomas, 7 (14.5%) nonseminomatous germ cell tumors, 2 (4.5%) Sertoli cell tumors, 12 (25%) benign forms (fibrosis, infarct, lipoma, mesothelial hyperplasia, adenomatoid tumor).
  • Dimension was particularly related to germ cell tumors (for dimensions between 16 and 32 mm relative risk ratio [RRR] = 13.97, p=0.0449).
  • Infertility proved significant in defining stromal tumors (RRR = 9,681, p=0.022) CONCLUSIONS: Although with the limits of a retrospective study consisting in an analysis of individual data, interesting correlations between malignant pathologies and the initial characteristics of impalpable sonographic lesions were revealed.
  • In particular an interesting correlation was found between the dimensions of the lesion and the malignant pathology and between Leydig cell tumor and infertility.

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094042.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  •  go-up   go-down


83. Phillips V, McCluggage WG, Young RH: Oxyphilic adenomatoid tumor of the ovary: a case report with discussion of the differential diagnosis of ovarian tumors with vacuoles and related spaces. Int J Gynecol Pathol; 2007 Jan;26(1):16-20
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxyphilic adenomatoid tumor of the ovary: a case report with discussion of the differential diagnosis of ovarian tumors with vacuoles and related spaces.
  • We describe an unusual example of ovarian adenomatoid tumor that was an incidental finding in the ovary of a 52-year-old woman and was characterized by cells with abundant eosinophilic cytoplasm, an occasional feature of the adenomatoid tumor but one that, in an ovarian example, may cause added diagnostic confusion to that already engendered by the rarity of this neoplasm in the ovary.
  • The typical numerous small vacuoles of the neoplasm sometimes had the appearance of signet ring cells.
  • Tumor cells were positive with broad-spectrum cytokeratins as well as mesothelial markers CK5/6, WT1, and calretinin.
  • [MeSH-major] Adenomatoid Tumor / diagnosis. Ovarian Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197891.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Rodríguez Portal JA, Rodríguez Becerra E, Rodríguez Rodríguez D, Alfageme Michavila I, Quero Martínez A, Diego Roza C, León Jiménez A, Isidro Montes I, Cebollero Rivas P: Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev; 2009 Feb;18(2):646-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
  • BACKGROUND: Malignant pleural mesothelioma (MPM) results from malignant transformation of mesothelial cells.
  • Past asbestos exposure represents a major risk factor for MPM and other benign pleural disease.
  • The aim of this study was to investigate serum levels of SMRP in malignant and nonmalignant asbestos-related pleural disease.
  • PATIENTS: Four groups of patients were investigated: group 1 composed of 48 healthy subjects, group 2 composed of 177 patients with previous asbestos exposure and no pleural disease, group 3 composed of 36 patients with MPM, and group 4 composed of 101 patients with previous asbestos exposure and benign pleural disease.
  • Subjects exposed to asbestos had higher SMRP concentrations than normal control subjects regardless of the presence of pleural disease.
  • CONCLUSIONS: These data attest to good diagnostic sensitivity and specificity of SMRP for the diagnosis of malignant mesothelioma.
  • [MeSH-major] Asbestosis / blood. Biomarkers, Tumor / blood. Membrane Glycoproteins / blood. Mesothelioma / blood. Pleural Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190155.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


85. Soini Y, Talvensaari-Mattila A: Expression of claudins 1, 4, 5, and 7 in ovarian tumors of diverse types. Int J Gynecol Pathol; 2006 Oct;25(4):330-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of claudins 1, 4, 5, and 7 in ovarian tumors of diverse types.
  • Strong expression of claudins 1, 4, and 7 was seen in benign and malignant epithelial ovarian tumors.
  • Expression of claudin 5, reported to be mainly present in endothelial cells, was seen in ovarian epithelial tumors, but with a significantly lower frequency than claudins 1, 4, and 7.
  • On the contrary, sex-cord stromal tumors and cysts, such as fibromas/thecomas, Sertoli-Leydig cell tumors, granulosa cell tumors, and follicular and luteinized cysts were mainly negative for claudins 1, 4, 5, and 7.
  • Interestingly, adenomatoid tumors did not express claudin 5, which is in agreement with their non-endothelial nature.
  • They were also negative for claudin 4, but expressed claudins 1 and 7, but to a lesser degree than epithelial lesions.
  • In immature teratomas, the epithelial component was usually positive whereas other components were negative for these claudins.
  • The results show that claudins 1, 4, and 7 are mainly expressed in ovarian epithelial tumors and can thus be used to indicate epithelial differentiation in them.
  • Eventhough considered an endothelial marker, claudin 5 was also present in a subset of epithelial lesions.
  • However, this claudin can be used to differentiate adenomatoid tumors from vascular lesions.
  • No significant difference was seen between epithelial benign and malignant lesions, except for claudin 5, which seemed stronger in malignant epithelial tumors.
  • [MeSH-minor] Adenomatoid Tumor / chemistry. Brenner Tumor / chemistry. Carcinoma / chemistry. Claudin-1. Claudin-4. Claudin-5. Claudins. Dysgerminoma / chemistry. Female. Humans. Immunohistochemistry. Krukenberg Tumor / chemistry. Ovarian Cysts. Sex Cord-Gonadal Stromal Tumors / chemistry. Teratoma / chemistry

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16990707.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLDN1 protein, human; 0 / CLDN4 protein, human; 0 / CLDN5 protein, human; 0 / CLDN7 protein, human; 0 / Claudin-1; 0 / Claudin-4; 0 / Claudin-5; 0 / Claudins; 0 / Membrane Proteins
  •  go-up   go-down


86. Kondi-Pafiti A, Kairi-Vassilatoul E, Spanidou-Carvouni H, Kontogianni-Katsarou K, Anastassopoulos G, Papadias K, Smyrniotis V: Extragenital cystic lesions of peritoneum, mesentery and retroperitoneum of the female. Clinicopathological characteristics of 19 cases. Eur J Gynaecol Oncol; 2005;26(3):323-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cysts measured 4-27 cm in diameter and were classified as: epithelial (7/19), mesothelial (5/19), vascular (2/19), parasitic (1/19) and developmental in origin (4/19).
  • Of the cases 18/19 were benign lesions and one case was a borderline mucinous cystic tumor.
  • The results are helpful in the correct classification of various tumors.
  • The treatment of choice is complete surgical resection of the tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Peritoneal Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Peritoneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991537.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


87. Neumann V, Löseke S, Tannapfel A: [Medical insurance aspects of peritoneal tumors with particular attention to peritoneal mesotheliomas]. Med Klin (Munich); 2009 Oct 15;104(10):765-71
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Medical insurance aspects of peritoneal tumors with particular attention to peritoneal mesotheliomas].
  • [Transliterated title] Versicherungsmedizinische Aspekte bei peritonealen Mesotheliomen und sonstigen peritonealen Tumoren.
  • Malignant peritoneal mesotheliomas arise mainly in male patients and the median age of initial diagnosis is about 56 years.
  • Epitheloid subtype predominates in peritoneal mesotheliomas.
  • Asbestos exposure is the best-known and most common risk factor associated with the development of both pleural and peritoneal mesotheliomas and, therefore, about 90% of cases can be assessed as asbestos-associated.
  • Patients with peritoneal mesotheliomas have distinctly higher asbestos burden of the lungs than patients with pleural mesotheliomas.
  • The mean latency period between exposure and diagnosis of peritoneal mesothelioma ranges from 35 to 40 years and is comparable to that of pleural mesothelioma.
  • Mesothelioma of the tunica vaginalis testis also belongs to the group of peritoneal mesotheliomas.
  • No significant evidence exists for the classification of well-differentiated papillary mesothelioma, solitary fibrous tumor, adenomatoid tumor, primary peritoneal serous borderline tumor, and benign multicystic mesothelioma as asbestos-associated tumors.
  • Except malignant mesotheliomas, the induction of other abdominal tumors is independent of an exposure to asbestos dust.
  • [MeSH-major] Asbestosis / epidemiology. Mesothelioma / epidemiology. National Health Programs / statistics & numerical data. Peritoneal Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Asbestos.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Ind Med. 1960 Oct;17:260-71 [13782506.001]
  • [Cites] Arch Pathol Lab Med. 2005 Mar;129(3):403-6 [15737040.001]
  • [Cites] Environ Res. 1984 Dec;35(2):531-51 [6391911.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Dec;19(6):1067-87, vi [16325124.001]
  • [Cites] Am J Surg Pathol. 1990 Mar;14(3):230-9 [2305929.001]
  • [Cites] Ann Oncol. 2007 Jun;18(6):985-90 [17030547.001]
  • [Cites] Am J Surg Pathol. 1995 Oct;19(10):1124-37 [7573671.001]
  • [Cites] Am J Clin Oncol. 2008 Feb;31(1):49-54 [18376228.001]
  • [Cites] Br J Ind Med. 1983 May;40(2):145-52 [6299326.001]
  • [Cites] Q J Med. 1976 Jul;45(179):427-49 [948545.001]
  • [Cites] Am J Gastroenterol. 1981 Apr;75(4):311-3 [7258177.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 1996;15(2-4):191-4 [9216805.001]
  • [Cites] Cancer. 1981 Jul 1;48(1):134-9 [7237380.001]
  • [Cites] Environ Health. 2008 Jan 24;7:4 [18218073.001]
  • [Cites] Histopathology. 1991 Dec;19(6):515-22 [1786936.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Sep 15;178(6):624-9 [18556631.001]
  • [Cites] Ultrastruct Pathol. 2002 Nov-Dec;26(6):355-63 [12537760.001]
  • [Cites] Am J Ind Med. 1988;14(3):331-9 [3189349.001]
  • [Cites] Histopathology. 2008 Jun;52(7):824-30 [18494612.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):724-37 [15981812.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1304-9 [11688466.001]
  • [Cites] Int J Urol. 2008 Jun;15(6):560-1 [18489651.001]
  • [Cites] Chest. 1980 Feb;77(2):133-7 [7353405.001]
  • [Cites] Pathologe. 1999 May;20(3):169-76 [10412176.001]
  • [Cites] Am J Pathol. 1995 Feb;146(2):344-56 [7856747.001]
  • [Cites] Cancer. 1988 May 15;61(10):2019-21 [3282640.001]
  • [Cites] Am J Surg Pathol. 1988 Oct;12(10):737-46 [3421410.001]
  • [Cites] Nat Med. 1997 Aug;3(8):908-12 [9256284.001]
  • [Cites] Hum Pathol. 1977 Jan;8(1):83-94 [844856.001]
  • [Cites] Swiss Surg. 2003;9(6):311-4 [14725101.001]
  • [Cites] Zentralbl Chir. 2001 Mar;126(3):229-32 [11301890.001]
  • [Cites] Adv Anat Pathol. 2006 Jan;13(1):16-25 [16462153.001]
  • [Cites] Histopathology. 2009 Jan;54(1):55-68 [19054156.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2437-46 [9874447.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1183-200 [10976692.001]
  • [Cites] Histopathology. 2002 Mar;40(3):237-44 [11895489.001]
  • [Cites] J Occup Environ Med. 2003 Apr;45(4):451-5 [12708149.001]
  • [Cites] Am J Epidemiol. 2004 Jan 15;159(2):107-12 [14718210.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1379-85 [8608519.001]
  • [Cites] Pathologe. 1989 Mar;10(2):114-7 [2717537.001]
  • [Cites] Arch Pathol Lab Med. 2007 Jan;131(1):138-44 [17227115.001]
  • [Cites] Curr Opin Pulm Med. 1999 Sep;5(5):326-31 [10461539.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2009 Apr 24;58(15):393-6 [19390506.001]
  • [Cites] Gynecol Oncol. 2005 Jul;98(1):161-7 [15894368.001]
  • [Cites] Int J Cancer. 1987 Jan 15;39(1):10-7 [3025107.001]
  • [Cites] J Surg Oncol. 2008 Sep 15;98(4):268-72 [18726890.001]
  • [Cites] J Surg Oncol. 2002 Apr;79(4):243-51 [11920782.001]
  • [Cites] Occup Environ Med. 1994 Dec;51(12):804-11 [7849863.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1336-46 [2766227.001]
  • [Cites] Am J Pathol. 1981 Mar;102(3):314-23 [7212016.001]
  • [Cites] Int Arch Occup Environ Health. 2001 Aug;74(6):383-95 [11563601.001]
  • [Cites] Cancer. 1975 Oct;36(4):1381-5 [1175135.001]
  • [Cites] Soz Praventivmed. 1982 Oct;27(5):220-2 [7158050.001]
  • [Cites] Occup Environ Med. 2007 Dec;64(12):839-42 [17567726.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(5):443-7 [2122588.001]
  • [Cites] Cancer Sci. 2006 Apr;97(4):292-5 [16630121.001]
  • [Cites] Chest. 1993 Apr;103(4 Suppl):373S-376S [8462328.001]
  • [Cites] Am J Surg Pathol. 1992 May;16(5):467-75 [1599025.001]
  • [Cites] Thorax. 1997 Jun;52(6):507-12 [9227715.001]
  • [Cites] World J Surg. 2006 Apr;30(4):560-6 [16547615.001]
  • [Cites] Chirurg. 2000 Aug;71(8):877-86 [11013806.001]
  • [Cites] Aktuelle Urol. 2006 Jul;37(4):281-3 [16878282.001]
  • [Cites] Am J Surg Pathol. 2008 Nov;32(11):1627-42 [18753943.001]
  • [Cites] Br J Dis Chest. 1983 Oct;77(4):321-43 [6357260.001]
  • [Cites] Adv Anat Pathol. 2009 Jan;16(1):62-4 [19098468.001]
  • [Cites] Environ Health Perspect. 1983 Nov;53:121-30 [6662082.001]
  • (PMID = 19856150.001).
  • [ISSN] 1615-6722
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 76
  •  go-up   go-down


88. Flores-Staino C, Darai-Ramqvist E, Dobra K, Hjerpe A: Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions. Lung Cancer; 2010 Apr;68(1):39-43
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions.
  • In effusion cytology, adjuvant techniques are often needed for the differentiation of reactive proliferating mesothelial cells and malignant cells.
  • In the case of malignancy the further challenge is to distinguish metastatic tumors from the primary malignant mesothelioma.
  • Moreover, it has been proposed that a homozygous deletion of the p16(INK4A) gene could more specifically identify malignant mesothelial cells among the exfoliated cells.
  • The cytological diagnosis was malignant in 29 cases, inconclusive in 24 cases and benign in 15 cases.
  • The independently verified final diagnoses were mesothelioma in 21 cases, metastatic cancer in 29 and benign in 18 cases.
  • The algorithm for aneuploidy distinguished almost all tested malignant conditions from benign ones, also those with inconclusive cytology.
  • The 9p21 locus, carrying the p16(INK4A) gene, was homozygously deleted in two of the metastatic cancers, while this was seen in 12 of the 21 malignant mesotheliomas.
  • [MeSH-major] Breast Neoplasms / diagnosis. In Situ Hybridization, Fluorescence / methods. Lung Neoplasms / diagnosis. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Solitary Fibrous Tumor, Pleural / diagnosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19523712.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Reagent Kits, Diagnostic
  •  go-up   go-down


89. Wheeler YY, Burroughs F, Li QK: Fine-needle aspiration of a well-differentiated papillary mesothelioma in the inguinal hernia sac: A case report and review of literature. Diagn Cytopathol; 2009 Oct;37(10):748-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration of a well-differentiated papillary mesothelioma in the inguinal hernia sac: A case report and review of literature.
  • Well-differentiated papillary mesothelioma (WDPM) is an uncommon subtype of epithelioid mesothelioma.
  • In contrast to malignant epithelioid mesothelioma, WDPM has a low malignant potential and an indolent clinical course.
  • WDPM may be difficult to diagnose and differentiate from benign reactive mesothelial cells and other malignant neoplasm on cytology specimens due to the presence of papillary or tubulopapillary clusters of tumor cells.
  • We report a case of a 63-year-old Asian male with a slowly growing left inguinal hernia mass for several years and a concurrent 8 cm mass in the peritoneal wall.
  • The cytology of ultrasound-guided fine-needle aspiration (FNA) of the left inguinal hernia and peritoneal masse reveal cellular specimens with numerous individual and tubulopapillary clusters of epithelioid mesothelial cells in a background of scant hyalinized material.
  • Tumor cells show minimal cytological atypia.
  • The differential diagnoses are broad and include reactive mesothelial cells, WDPM, and other malignant neoplasm.
  • It is important to recognize this entity in the differential diagnosis, because the clinical management of WDPM is quite different from that of malignant neoplasm.
  • [MeSH-major] Hernia, Inguinal / pathology. Inguinal Canal / pathology. Mesothelioma / pathology. Peritoneal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19373910.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


90. Creaney J, Segal A, Sterrett G, Platten MA, Baker E, Murch AR, Nowak AK, Robinson BW, Millward MJ: Overexpression and altered glycosylation of MUC1 in malignant mesothelioma. Br J Cancer; 2008 May 6;98(9):1562-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression and altered glycosylation of MUC1 in malignant mesothelioma.
  • MUC1/EMA expression has been observed in the majority of epithelioid mesotheliomas.
  • However, little is known of the characteristics of MUC1/EMA in mesothelioma.
  • Herein, we studied the cell surface and soluble expression of the MUC1/EMA glycoprotein, and determined the mRNA and genomic expression profiles in mesothelioma.
  • MUC1 mRNA expression was significantly higher in mesothelioma samples than in benign mesothelial cells.
  • Seven of 9 mesothelioma samples expressed MUC1-secreted mRNA isoform in addition to the archetypal MUC1/transmembrane form.
  • CA15.3 (soluble MUC1) levels were significantly higher in the serum of mesothelioma patients than in healthy controls but were not significantly different to levels in patients with benign asbestos-related disease.
  • CA15-3 in effusions could differentiate malignant from benign effusions but were not specific for mesothelioma.
  • Thus, as in other cancers, alterations in MUC1 biology occur in mesothelioma and these results suggest that specific MUC1 characteristics may be useful for mesothelioma diagnosis and should also be investigated as a potential therapeutic target.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Mesothelioma / diagnosis. Mesothelioma / metabolism. Mucin-1 / metabolism. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Nov;81(6):1059-65 [10576665.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5129-35 [16951230.001]
  • [Cites] Cytopathology. 2000 Jun;11(3):139-51 [10877273.001]
  • [Cites] Blood. 2000 Nov 1;96(9):3102-8 [11049990.001]
  • [Cites] Lung Cancer. 2001 Jan;31(1):9-16 [11162861.001]
  • [Cites] Curr Opin Mol Ther. 2001 Feb;3(1):102-5 [11249725.001]
  • [Cites] Int J Cancer. 2002 Jul 10;100(2):166-71 [12115565.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):209-21 [12463741.001]
  • [Cites] Clin Breast Cancer. 2003 Feb;3 Suppl 4:S134-8 [12620150.001]
  • [Cites] Lung Cancer. 2003 Jun;40(3):289-94 [12781427.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1031-51 [12883236.001]
  • [Cites] Histopathology. 2004 Feb;44(2):147-55 [14764058.001]
  • [Cites] Crit Rev Clin Lab Sci. 2004;41(2):189-231 [15270554.001]
  • [Cites] Arch Pathol Lab Med. 2004 Oct;128(10):1131-5 [15387710.001]
  • [Cites] Ann Intern Med. 1972 Oct;77(4):507-13 [4642731.001]
  • [Cites] Br J Cancer. 1985 Sep;52(3):347-54 [3899155.001]
  • [Cites] Cancer Res. 1993 Feb 15;53(4):755-61 [7679050.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23 Suppl):5847s-5851s [7493358.001]
  • [Cites] Tumour Biol. 1998;19 Suppl 1:88-99 [9422093.001]
  • [Cites] Tumour Biol. 1998;19 Suppl 1:111-7 [9422095.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):583-90 [9452278.001]
  • [Cites] Diagn Cytopathol. 2005 Mar;32(3):156-9 [15690334.001]
  • [Cites] Lancet. 2005 Jul 30-Aug 5;366(9483):397-408 [16054941.001]
  • [Cites] Oncologist. 2005 Aug;10(7):501-7 [16079317.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1295-304 [15976813.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):405-11 [16052519.001]
  • [Cites] Cancer Immunol Immunother. 2006 Jan;55(1):63-7 [15864588.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):869-77 [16467101.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5910-8 [16740731.001]
  • [Cites] J Urol. 2006 Jul;176(1):91-5 [16753376.001]
  • [Cites] Tumour Biol. 2000 Jul-Aug;21(4):197-210 [10867613.001]
  • (PMID = 18454162.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2391110
  •  go-up   go-down


91. Manosca F, Schinstine M, Fetsch PA, Sorbara L, Maria Wilder A, Brosky K, Erickson D, Raffeld M, Filie AC, Abati A: Diagnostic effects of prolonged storage on fresh effusion samples. Diagn Cytopathol; 2007 Jan;35(1):6-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We sought to determine if effusion specimens are suitable for morphologic, immunocytochemical, and DNA-based molecular studies after prolonged periods of refrigerated storage time.
  • Specimens evaluated included four pleural (3 benign, 1 breast adenocarcinoma) and six peritoneal (2 ovarian adenocarcinomas, 1 malignant melanoma, 2 mesotheliomas, 1 atypical mesothelial) effusions.
  • [MeSH-minor] Adult. Biomarkers, Tumor. DNA, Neoplasm / analysis. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction. Time Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17173298.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


92. Grasso M, Blanco S, Raber M, Nespoli L: Elasto-sonography of the testis: preliminary experience. Arch Ital Urol Androl; 2010 Sep;82(3):160-3
MedlinePlus Health Information. consumer health - Testicular Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the remaining 3 cases it allowed a better characterization of 2 small benign tumors and of an intratesticular haematoma.
  • Infact elastosonography resulted helpful in the determination of 2 small lesions diagnosticated after surgery as Sertoli tumor and adenomatoid tumor of the testis, respectively in a third case the elastosonography identified an intraparenchimal hematoma (confirmed after surgical exploration )in the differential diagnosis with a solid tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21121434.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


93. Agaba EI, Ekwempu CC, Ugoya SO, Echejoh GO: Meigs' syndrome presenting as haemorrhagic pleural effusion. West Afr J Med; 2007 Jul-Sep;26(3):253-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The association of a benign ovarian tumor with ascites and hydrothorax that resolve after tumor resection, known as Meigs syndrome is a rare clinical entity.
  • Rarer still is the haemorrhagic form of the syndrome OBJECTIVE: To describe a case of benign ovarian tumour associated with ascites and bloody pleural effusion.
  • METHODS: A thirty-seven year old woman was referred for the further management of a pleural effusion.
  • Repeated pleural fluid cytology showed mesothelial cells but was negative for malignancy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18399347.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


94. Savelli L, Ghi T, De Iaco P, Ceccaroni M, Venturoli S, Cacciatore B: Paraovarian/paratubal cysts: comparison of transvaginal sonographic and pathological findings to establish diagnostic criteria. Ultrasound Obstet Gynecol; 2006 Sep;28(3):330-4
MedlinePlus Health Information. consumer health - Ovarian Cysts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological analysis of the masses containing papillary projections diagnosed eight cystadenofibromas, five cystadenomas and two serous papillary borderline tumors, while analysis of paraovarian cysts without papillations revealed benign, serous cysts of paramesonephric or mesothelial origin.
  • Their risk of malignancy is low if no papillary projections are detected at transvaginal sonography, but when mural proliferations are present a borderline tumor can be found at pathological examination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 ISUOG. Published by John Wiley & Sons, Ltd.
  • (PMID = 16823765.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


95. Hecht JL, Pinkus JL, Pinkus GS: Monoclonal antibody MOC-31 reactivity as a marker for adenocarcinoma in cytologic preparations. Cancer; 2006 Feb 25;108(1):56-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: It has been shown previously that detection of the epithelial membrane antigen using the mouse monoclonal antibody MOC-31 has diagnostic utility in the distinction between mesothelioma and metastatic carcinoma in body fluids.
  • METHODS: The authors evaluated 112 cell blocks for MOC-31 immunoreactivity, including 17 mesotheliomas, 86 metastatic adenocarcinomas from various sites, and 9 control fluids from patients with nonneoplastic conditions.
  • Sixteen of 17 mesothelioma samples were negative.
  • In all but 1 sample of adenocarcinoma, > 90% of tumor cells present showed reactivity, and the staining intensity consistently was strong.
  • Staining of scattered, morphologically benign mesothelial cells was observed in nine samples but did not interfere with interpretation.
  • CONCLUSIONS: On the basis of the staining profile, MOC-31 represented an effective marker for metastatic carcinoma in cell block preparations and may aid in distinguishing between benign and malignant mesothelial cells in these tumors.
  • [MeSH-major] Adenocarcinoma / secondary. Antibodies, Monoclonal. Biomarkers, Tumor / analysis. Mesothelioma / pathology

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16329115.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Mucin-1
  •  go-up   go-down


96. García-González J, Villanueva C, Fernández-Aceñero MJ, Paniagua P: Paratesticular desmoplastic small round cell tumor: case report. Urol Oncol; 2005 Mar-Apr;23(2):132-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paratesticular desmoplastic small round cell tumor: case report.
  • BACKGROUND: The desmoplastic small round cell tumor has recently been separated from other small round cell tumors because of its characteristic pathological and clinical features.
  • They are usually intra-abdominal tumors affecting young people and have classically been associated with a bad prognosis.
  • However, in recent years there have reports on desmoplastic small round cell tumors affecting other body regions, including the paratesticular area.
  • CASE PRESENTATION: We report the case of a 23-year-old male, that consulted on a progressive enlargement of the right hemiscrotum in the last year and a half.
  • Physical examination revealed a round elastic firm 2 to 3 cm mass distal to the tail of the epididymis, which was excised with a preoperative diagnosis of adenomatoid tumor.
  • However, histological and immunohistochemical diagnosis confirmed a desmoplastic small round cell tumor.
  • Today, 6 years after diagnosis the patient remains well and free of disease.
  • CONCLUSIONS: Recent reviews on desmoplastic small round cell tumor affecting the paratesticular area have shown a better prognosis for tumors of this origin compared to abdominal ones.
  • We should include this lesion among the differential diagnosis of paratesticular tumors, mainly in children and adolescents.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Humans. Male

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15869999.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Arsene D, Georgescu A, Dănăilă L, Ardeleanu C: Giant intracranial endolymphatic sac tumor (ELST). Case presentation and histogenetic considerations. Rom J Morphol Embryol; 2008;49(1):85-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant intracranial endolymphatic sac tumor (ELST). Case presentation and histogenetic considerations.
  • We present a giant tumor of the skull base compressing the brain in a 40-years-old man.
  • The tumor was policystic at imaging.
  • Its histopathology, immunohistochemical profile and long evolution suggest an endolymphatic sac tumor (ELST), a rare case of neoplasia.
  • This could be from either the organ of Corti or some local cells that generate a resemblance with a systemic tumor, the so-called benign mesothelioma.
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Humans. Male. Tumor Burden

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18273509.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


98. Ribeiro BF, Iglesias DP, Nascimento GJ, Galvão HC, Medeiros AM, Freitas RA: Immunoexpression of MMPs-1, -2, and -9 in ameloblastoma and odontogenic adenomatoid tumor. Oral Dis; 2009 Oct;15(7):472-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoexpression of MMPs-1, -2, and -9 in ameloblastoma and odontogenic adenomatoid tumor.
  • OBJECTIVE: The aim of this study was to evaluate and compare the expression of metalloproteinases-1, -2, and -9 in solid ameloblastoma and adenomatoid odontogenic tumor.
  • METHODS: A total of 20 cases of solid ameloblastoma and 10 cases of adenomatoid odontogenic tumors were selected and immunohistochemically assessed.
  • RESULTS: Matrix metalloproteinase (MMP)-1 showed a predominant expression in both tumors and was found in stroma and parenchyma.
  • For MMP-2, there was a varied expression, with 80% and 60% of immunoreactive tumor cells in ameloblastoma and adenomatoid odontogenic tumor respectively.
  • Regarding stromal cells, 65% of ameloblastomas and 80% of adenomatoid odontogenic tumors showed positivity.
  • There was immunoexpression of the MMP-9 in parenchymal and stromal cells in all cases of both tumors analyzed.
  • CONCLUSION: The results suggest that these metalloproteinases are related to growth and progression of tumors analyzed, and particularly in ameloblastoma, its highest aggressiveness may be, in part, a result of the active participation of the stromal cells and their products, such as the MMPs studied.
  • [MeSH-major] Ameloblastoma / metabolism. Matrix Metalloproteinase 1 / biosynthesis. Matrix Metalloproteinase 2 / biosynthesis. Matrix Metalloproteinase 9 / biosynthesis. Odontogenic Tumors / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522745.001).
  • [ISSN] 1601-0825
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


99. Minhas K, Barakzai A, Qureshi A: Fibromatous periorchitis. J Pak Med Assoc; 2009 Jan;59(1):47-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although fibrous pseudotumours of this region are uncommon, they are reported to be the second most common benign paratesticular lesion after adenomatoid tumours.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19213380.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


100. Afify A, Pang L, Howell L: Diagnostic utility of CD44 standard, CD44v6, and CD44v3-10 expression in adenocarcinomas presenting in serous fluids. Appl Immunohistochem Mol Morphol; 2007 Dec;15(4):446-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to evaluate the extent to which metastatic adenocarcinomas in effusions express CD44s, CD44v6, and CD44v3-10 and to assess their diagnostic utility in distinguishing reactive mesothelial cells from adenocarcinomas.
  • Archival paraffin-embedded cell blocks of serous fluids from 23 cases of benign effusions containing reactive mesothelial cells and 45 cases of malignant effusions with metastatic adenocarcinoma (18 ovarian, 11 pulmonary, 9 gastrointestinal, and 7 breast) were retrieved from the surgical pathology files.
  • Strong staining in at least 10% of the tumor cells was required to consider the case positive for the particular marker.
  • In benign effusions mesothelial cells expressed CD44s in 22 cases (96%), CD44v6 in 1 cases (4%) and CD44v3-10 in 0 cases (0%).
  • CD44s immunostaining can be used as a reliable marker to identify reactive mesothelial cells, meanwhile CD44v3-10 immunostaining can detect majority of adenocarcinomas in malignant effusions.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091389.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44 protein, human; 0 / CD44v6 antigen; 0 / Glycoproteins
  •  go-up   go-down






Advertisement